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ABSTRACT 
 
The most significant problem for cancer patients is the dissemination of cancer cells and the 
formation of metastatic disease.  Emblematic of the problem is the clinical progression seen in 
most patients with osteosarcoma, where metastasis to the lung is the most common cause of 
death. The primary research need in the field is to understand the biology of metastasis in 
osteosarcoma so as to improve outcomes for future patients. Unraveling the complexity of 
metastasis demands a focus on new tools, reagents, and biology in order to investigate 
hypotheses.  Accordingly, this body of work introduces an outcome-linked human ostoesarcoma 
tissue microarray (new tool) used to detect and validate protein biomarkers across a variety of 
patients and an ex vivo pulmonary metastasis assay (new reagent) that allows real-time 
assessment of metastatic progression in a relevant microenvironment. Furthermore, cancer cells 
are believed to efficiently regulate protein translation at specific times and locations in a cell in 
response to changes in their environment. Preventing the dynamic regulation of these proteins 
(many of which have been associated with cancer/metastasis) may be an effective treatment 
strategy in the management of metastasis. Within the process of protein translation the 
abundance and activation of the mRNA cap-binding phosphoprotein, eukaryotic initiation factor 
4E (eIF4E) is considered to be both rate and process limiting. We describe for the first time, the 
biological role of eIF4E (new biology) in metastatic osteosarcoma. We employed a comparative 
approach to study the biology of metastasis in osteosarcoma by using tissues and reagents from 
murine and human osteosarcomas. Using overexpression and knockdown techniques we 
modulated eIF4E expression in murine and human osteosarcoma cell lines and then evaluated the 
consequences at various steps within the metastatic cascade in vitro and in vivo. We found that 
suppression of eIF4E significantly delayed migration and reduced the number and size of 
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colonies that formed in soft agar. Additionally, suppression of eIF4E inhibited spontaneous 
pulmonary metastases. eIF4E overexpression did not change the phenotype of previously non-
metastatic cells. These results suggest eIF4E may be a necessary, but not sufficient, requirement 
for metastasis in osteosarcoma. The goals of this research were to utilize these new tools and 
reagents to identify proteins and/or processes that define the metastatic phenotype of 
osteosarcoma and to use our newfound understanding of eIF4E in osteosarcoma metastasis to 
develop novel therapeutic strategies to prevent growth of metastases and improve treatment 
outcomes for patients. 
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Chapter 1. Background 
 
Osteosarcoma Metastasis 
 The single most significant negative prognostic factor in the treatment of cancer is the 
development of metastatic disease. Emblematic of the problem is the clinical progression seen in 
most patients with osteosarcoma. For most pediatric osteosarcoma patients, despite successful 
management of the primary tumor through multimodality approaches, the development of 
metastases, commonly to the lungs, is the cause of death. Less than 30% of patients that present 
with metastatic disease at the time of diagnosis will survive. Long-term outcomes for 
osteosarcoma patients have not improved in over 20 years (Meyers, 2009). The metastatic 
cascade is a complex multistage process. In order for a cancer cell to become a clinically 
detectable lesion, it must separate from the primary tumor, invade the surrounding tissues and 
basement membranes, enter and survive the circulation, arrest, extravasate, and then go on to 
survive, proliferate, and develop a blood supply at the secondary site.  Each step is subject to a 
wide variety of influences such as apoptotic death or immunological response, thus at any point 
in the sequence the tumor cells may not survive. Again, metastasis remains a major problem in 
the management of osteosarcoma since the majority of mortality is associated with disseminated 
disease rather than the primary tumor. Opportunities to improve outcomes for patients who 
present with metastases and those at risk for metastatic progression require an improved 
understanding of tumor biology and metastasis. The primary research need in the field is to 
understand the biology of metastasis in osteosarcoma.  The complexity of metastasis remains an 
enigma and therefore demands a focus on new tools and reagents in order to explore new 
hypotheses in the field.   
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Ezrin 
Ezrin is a metastasis-associated protein. The genetic determinants of pulmonary 
metastasis in osteosarcoma were defined using a murine cDNA microarray to compare gene 
expression between the primary tumors of two clonally related highly metastatic (K7M2) and 
poorly metastatic (K12) murine models of osteosarcoma (Khanna et al., 2001). The differentially 
expressed genes were assigned to six nonmutually exclusive metastasis-associated categories 
(based on literature review). Functional evaluation of the mouse models via multiple metastasis-
associated assays (e.g., motility, invasion, and adherence) identified 10 genes that were 
considered to most likely describe the differences in the metastatic behavior of the two models. 
Ezrin was one of the 10 genes identified. After identifying ezrin as a gene that explained 
metastasis-associated differences in a mouse model, Khanna et al., (2004) further studied ezrin to 
determine its role in metastasis. Suppression of ezrin expression or mutation in ezrin 
significantly reduced metastasis in both osteosarcoma (Khanna et al., 2004) and 
rhabdomyosarcoma (Yu et al., 2004) model systems. To further demonstrate the relevance of the 
role of ezrin in metastasis, findings were extended to other species. High ezrin levels were 
associated with poor osteosarcoma prognosis in pet dogs and children (Khanna et al., 2004). 
High ezrin levels were linked to increasing rhabdomyosarcoma grades in humans (Yu et al., 
2004). Collectively, these findings provide a strong argument for the metastasis-promoting 
function of ezrin.  
Ezrin functions as a linker protein connecting the actin cytoskeleton and the plasma 
membrane. This cytoskeleton linkage to the cell membrane allows the cell to physically engage 
its microenvironment and results in a functional facilitation of many cell-signaling pathways 
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previously shown to be important in metastasis (Madan et al., 2006; Tsukita and Yonemura, 
1997). The mechanisms that may explain the ezrin-dependent effects on osteosarcoma metastasis 
are not well understood. 
 
Ezrin and Translation 
In an attempt to elucidate ezrin’s role in metastasis, our laboratory used two 
fundamentally different noncandidate experiments to assess: (1) ezrin’s physical and functional 
connections between various cell membrane proteins and the actin cytoskeleton (Clark et al., 
2000; Ohtani et al., 2002) and (2) to define changes in gene expression following the suppression 
of ezrin, using stable expression of a full-length antisense ezrin in the highly metastatic K7M2 
murine osteosarcoma cell line. More specifically, a proteomic approach based on affinity 
chromatography coupled with tandem mass spectrometry mass spectrometry (MS/MS) was 
utilized to identify ezrin-binding proteins, and murine cDNA microarrays were used to identify 
cDNAs that were differentially expressed in murine osteosarcoma cells. First we found 181 
differentially expressed genes then, we applied functional assessment of these outliers and found 
a disproportionate number of ezrin binding proteins that had functions linked to protein 
translation and translation initiation. Accordingly, an emerging hypothesis from the affinity 
chromatography and microarray experiments was that ezrin contributes to metastasis through 
modulation of translation and translation initiation. 
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Translation and Translation Initiation in Metastasis 
 
Translation is the second process of protein biosynthesis, which is part of the overall 
process of gene expression. It is necessarily preceded by transcription and has four phases: 
activation, initiation, elongation, and termination. In translation, messenger RNA (mRNA) which 
is used as a template to guide synthesis, is decoded to produce a specific polypeptide (Lehninger 
et al., 1993). The initiation phase of translation is considered to be rate limiting in the process of 
translation. Initiation involves the small subunit of the ribosome binding to the 5’end of mRNA 
with the assistance of initiation factors (IFs) (Pain, 1996). There is now a growing body of 
evidence that links dysregulation of protein synthesis and malignant progression of cancer. 
Clemens and Bommer  (1999) have discussed the many ways in which translational control is 
relevant to the topic of metastasis. For example, the efficiency of expression of important 
proteins involved in cell growth regulation, proliferation or cell death may be controlled at the 
translational level by changes in the activity of components of the protein synthesis machinery. 
Indeed, to progress through the metastatic cascade requires cooperative function of numerous 
proteins that facilitate invasion, survival, and angiogenesis.  Although expression of these 
proteins may be regulated at many levels by various stimuli, translation of these metastasis-
associated proteins is regulated primarily by eukaryotic initiation factor 4E (eIF4E) (Clemens 
and Bommer, 1999). 
 
eIF4E 
eIF4E was one of the candidates taken from the list of ezrin-associated outliers generated 
from the murine cDNA microarray experiments conducted in our laboratory. Indeed, eIF4E was 
 5 
differentially expressed in the microarray comparison of high- versus low-ezrin/metastatic 
murine osteosarcoma cells. eIF4E is a 25 kDa cytosolic protein that binds to the 7-methyl 
guanosine cap at the 5’ UTR of cellular mRNAs during translation initiation. Since eIF4E is 
found in much lower concentrations than other translation initiation factors, it is the rate-limiting 
component in translation initiation (Rhoads et al., 1993; Sonenburg and Gingras, 1998). The 
activity of eIF4E is modulated by phosphorylation and its interaction with eIF4E-binding 
proteins (4E-BPs) (Flynn and Proud, 1996; Raught and Gingras, 1999). Under normal cellular 
conditions, eIF4E is bound by inhibitory 4E-BPs. These 4E-BPs block eIF4E from interaction 
with eIF4G, preventing the assembly of the eIF4F complex. Extracellular stimuli such as growth 
factors, hormones, mitogens, amino acids, cytokines and G-protein coupled receptor agonists 
induce 4E-BP phosphorylation at multiple sites (Gingras, 2001; Gingras et al., 1999). 
Phosphorylation dislodges the inhibitory 4E-BPs from eIF4E enabling it to deliver mRNAs 
effectively to the eIF4F complex and facilitating translation by the eIF4F complex (Raught and 
Gingras, 1999).  
eIF4E is an important modulator of cell growth and proliferation and is overexpressed in 
a number of malignancies including lymphomas, cancers of the breast, lung, head and neck, 
bladder, prostate, colon and rectum, esophagus, skin, and cervix (De Benedetti and Graff, 2004; 
Matthews-Greer J, 2005; Salehi Z, 2006; Salehi Z, 2007; Sonenburg and Gingras, 1998). eIF4E 
specifically enhances translation of distinct oncogenic transcripts (weak mRNAs) that are 
translationally repressed under normal cellular conditions. These weak mRNAs almost 
universally encode for growth regulatory proteins. It is likely that upregulation of these gene 
products enables tumorigenesis and ultimately metastatic progression. Preventing the dynamic 
regulation of these proteins may be an effective treatment strategy in the management of 
 6 
metastasis. 
 
Statement of Research Problem and Objectives 
I am interested in defining the role of eIF4E in metastatic osteosarcoma. Cancer cells are 
believed to efficiently regulate protein translation at specific times and locations in a cell in 
response to changes in their environment. Within translation initiation the abundance and 
activation of the mRNA cap-binding phosphoprotein, eIF4E is considered to be both rate- and 
process-limiting. While eIF4E has been studied in a variety of epithelial tumors, there is little 
known about eIF4E in osteosarcoma. I propose to define the biological role of eIF4E in the 
metastatic phenotype of osteosarcoma cells (in vitro) and transplantable murine models of 
osteosarcoma (in vivo).  Throughout these studies I will ask questions regarding eIF4E 
expression and activity using murine and human osteosarcoma cell lines. This understanding will 
facilitate the use of novel inhibitors of eIF4E and translation initiation currently under 
development in our laboratory and elsewhere. 
 
Over-riding Hypothesis 
The metastatic success of osteosarcoma is linked to enabled translational machinery, 
defined by the expression and activity of eIF4E. This hypothesis will be tested through a series 
of experiments some of which utilize new tools (human osteosarcoma tissue microarray (TMA)) 
and reagents (ex vivo pulmonary metastasis assay (PuMA)) developed in our laboratory in an 
attempt to help elucidate the underlying steps involved in tumor dissemination, colonization, and 
metastatic progression.   
 
 7 
Specific Aim 1 
Evaluation of eIF4E expression in osteosarcoma tissues. A large number of 
retrospectively collected human osteosarcoma patient samples and associated clinical outcomes 
were used to design and assemble an outcome-linked osteosarcoma TMA that will enable 
biomarker and target evaluation in osteosarcoma. The TMA is now available as a community 
resource. I have used this newly developed tool to survey eIF4E in these osteosarcoma patients 
by immunohistochemistry, for expression and an association with clinical outcome.  
 
Hypotheses: 
1. eIF4E is expressed in human osteosarcoma tissues. 
 
2. Patients expressing higher-intensity staining of eIF4E will have a poorer clinical outcome 
(shorter disease-free intervals) than patients expressing lower staining intensities. 
 
Specific Aim 2 
Design a simple assay in which the process of metastatic progression at a secondary site 
(the lung) can be reproduced and studied over time. To address the unmet need for an assay that 
recapitulates the cellular and microenvironmental complexity of the metastatic site within a 
native 3-dimensional architecture, while allowing an “open window” for evaluation of metastatic 
progression, we developed an ex vivo pulmonary metastasis assay (PuMA). This assay allows 
real-time metastatic progression of GFP-expressing cancer cells in lung tissue. The PuMA 
successfully predicted high- and low-metastatic phenotypes of human and mouse cancer cell 
lines and was used for rapid screening of novel therapeutic agents at several dose and schedule 
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combinations. 
 
Hypothesis: 
The PuMA assay will predict the in vivo behavior of high- and low-metastatic human and 
mouse osteosarcoma cells. 
 
Specific Aim 3 
  Define the biological role of eIF4E in the in vitro metastatic phenotype of murine and 
human osteosarcoma cells. Modulation of eIF4E expression in murine and human osteosarcoma 
cell lines, using overexpression and shRNA knock-down techniques will allow me to determine 
whether eIF4E is necessary and/or sufficient for the steps of the metastatic cascade in vitro. 
 
Hypotheses: 
 
1. eIF4E  is expressed in murine and human osteosarcoma cell lines. 
 
2. eIF4E is differentially expressed in clonally related mouse and human osteosarcoma cell 
lines. 
 
3. Highly metastatic mouse and human cell lines will express higher levels of eIF4E than 
their clonally related low metastatic partners. 
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4. eIF4E overexpression in poorly metastatic mouse (K12) and human (HOS) 
osteosarcaoma cells will result in increased anchorage-independent growth, proliferation, 
motility, and migration as compared to controls. 
 
5. eIF4E knockdown in highly metastatic human (HOS-MNNG) osteosarcaoma cells will 
result in decreased anchorage-independent growth, proliferation, motility, and migration 
as compared to controls. 
 
Specific Aim 4 
Define the biological role of eIF4E in the in vivo metastatic phenotype of osteosarcoma, 
using transplantation of murine and human cells to mice. Informative cell lines in which eIF4E 
has been appropriately modulated will be used to study the in vivo roles for eIF4E in 
osteosarcoma murine models. 
 
Hypotheses: 
 
1. Overexpression of eIF4E in poorly metastatic mouse (K12) and human (HOS) 
osteosarcoma cell lines will increase primary tumor growth. 
 
2. Overexpression of eIF4E in poorly metastatic mouse (K12) and human (HOS) 
osteosarcoma cell lines will lead to a more aggressive metastatic phenotype in vivo. 
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3. Suppression of eIF4E in highly metastatic human (HOS-MNNG) osteosarcoma cells will 
impair in vivo metastasis.   
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Chapter 2.  A Connection Between Osteosarcoma Metastasis and Protein 
Translation: A Review 
 
Osteosarcoma 
Osteosarcoma (OS) is a rare malignant tumor of bone, arising from the malignant 
transformation of mesenchymal cells which have or will differentiate along the bone lineage and 
consequently produce osteoid (Kansara and Thomas, 2007; Malawar et al., 2005). While OS can 
arise in any bone, the most common sites of primary tumors are the distal femur, proximal tibia, 
and proximal humerus. Beyond primary tumor growth in the appendicular and less commonly, 
the axial skeleton, a defining feature of OS biology is its high propensity for pulmonary 
metastasis (90% of metastases are to the lung) (Krishnan et al., 2005). These defining features of 
OS are shared between both human and canine OS patients.  This review describes the human 
disease, discusses cross-species comparative opportunities along with the common issue of 
metastasis, and introduces our interest in translation and its potential link to metastasis.  
 
Osteosarcoma in pediatric patients   
OS may occur at any age however it has a peak incidence in the second decade of life 
with a second smaller peak of incidence in the elderly population (after the age of 50 years) 
(Hayden and Hoang, 2006; Kansara and Thomas, 2007).  Although rare, it is the most common 
pediatric bone malignancy in the United States (Gurney, 1999).  Approximately 800-1000 cases 
of OS are diagnosed in the United States each year and about half of these patients are teenagers 
(Kansara and Thomas, 2007; Wang, 2005).  OS occurs most frequently during the adolescent 
growth spurt in areas of rapid bone growth suggesting a relationship between rapid 
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growth/growth factors and risk of tumor formation (American Cancer Society, 
http://www.cancer.org/docroot/home/index.asp).  OS may occur more frequently in males than 
females (60% versus 40%) and slightly more often in African Americans than Caucasians 
(Gurney, 1999). 
Fifty years ago, when surgery was the only available treatment, a diagnosis of 
osteosarcoma was often fatal.  Patients had only a 15-20% chance of cure (Dahlin and Coventry, 
1967; Hayden and Hoang, 2006).  Fortunately, advances in chemotherapy including the 
introduction of single agent and combination chemotherapy along with orthopedic surgical 
techniques in the 1980s and 1990s increased survival rates dramatically. Today, patients with 
localized disease at presentation have a 65-70% chance of 5-year relapse-free survival (Bielack 
et al., 2002; Hayden and Hoang, 2006; Kansara and Thomas, 2007; Meyers, 2009).  Remaining 
patients will relapse (primarily to the lung) within the first 5 years, attesting to the fact that these 
patients have undetectable metastatic disease at diagnosis. The prognosis for patients with OS 
depends mainly on whether metastases are detectable at presentation.  Currently, up to 20-25% 
of newly diagnosed patients have detectable metastases at diagnosis (Hattinger et al., 2010). 
Patients presenting with metastases have a poor prognosis, with long-term survival rates of 10-
30% (Meyers, 2009). Other prognostic indicators for early relapse include size and location of 
the primary tumor, response to preoperative (neoadjuvant) chemotherapy and surgical success 
(Bielack et al., 2002). A combined approach of surgical removal of the primary tumor and 
systemic chemotherapy are currently employed to treat OS. Presently, standard chemotherapy 
protocols are based on neoadjuvant chemotherapy followed by surgical removal of the tumor and 
postoperative (adjuvant) chemotherapy. The use of neoadjuvant chemotherapy has the advantage 
of down-staging the size of the primary tumor and as such providing a more successful 
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opportunity for resection as well as providing an opportunity to histologically evaluate 
chemotherapy-induced tumor necrosis in the resected specimen. Importantly, neoadjuvant 
chemotherapy also delays the urgency for surgery. The Huvos grading system is a noninvasive 
quantitative estimate of the percentage of tumor cell necrosis (death) observed in the tumor after 
surgery. Patients showing tumor necrosis in at least 90% of the resected tumor specimen are 
classified as good responders (Huvos score 3 or 4). Importantly, the degree of necrosis in OS 
following neoadjuvant chemotherapy before surgery may yield prognostic information (event-
free survival) that is useful for subsequent patient treatment. Chemotherapy protocols used as a 
follow-up to definitive surgical resection involve multiple agents and may include methotrexate 
(M), adriamycin (A), doxorubicin (D), cisplatin (C), and ifosphamide (I) (Hayden and Hoang, 
2006).  The European and American Osteosarcoma Study (EURAMOS) group was founded in 
2001. A major goal of the group is to improve survival from osteosarcoma through conducting 
large randomized studies.  The EURAMOS I trial is designed to optimize treatment strategies for 
resectable OS based on histological response (Huvos score) to pre-operative chemotherapy 
(http://www.ctu.mrc.ac.uk/euramos). In this study, the Huvos score identifies patients as either 
good or poor responders. Patients who achieve a good histological response to pre-operative 
chemotherapy, have considerably better survival than those who have a poor response. Five-year 
survival for those with good response is approximately 75-80%, compared to 45-55% for those 
with poor response (Bielack et al., 2002; Whelan et al., 2000). The current treatment backbone 
used as first line therapy in patients includes cisplatin, doxorubicin and methotrexate. The 
study’s objectives are: (1) examine whether the addition of ifosfamide and etoposide (IE) to post-
operative chemotherapy improves event-free survival for patients with a poor histological 
response to pre-operative chemotherapy and (2) examine whether the addition of Interferon-∝ 
 18 
(IFN-∝) as maintenance therapy after post-operative chemotherapy improves event-free survival 
for patients with a good histological response to pre-operative chemotherapy. 
 Despite intensification of chemotherapy and multimodality treatments for OS, no 
improvements in long-term survival have been seen in over 20 years. The primary cause of death 
for patients continues to be the development of metastasis.  Patients that present with metastatic 
or recurrent disease have a worse clinical outcome than patients without evident metastases at 
diagnosis in spite of aggressive surgical and chemotherapeutic approaches.  Previous studies 
have shown that the overall survival rate among patients with localized OS, without detectable 
metastases, is approximately 60–70% (Goorin et al., 1984) whereas survival rate reduces to 10–
30% in patients with detectable metastatic disease (Goorin et al., 1984; Han, 1981; Ward, 1994). 
In order for patient outcomes to improve, we must improve our understanding of the biology of 
metastasis. 
 
Cross-species comparisons  
Cross-species comparative opportunities to understand osteosarcoma biology and therapy 
are strong. Companion animals naturally develop OS and the disease is almost identical in dogs 
and people. The clinical presentation, biology, treatment, complications, and outcomes are 
similar in both dogs and humans, although human patients have better outcomes and the 
incidence of OS is much greater in dogs (Withrow and Wilkins, 2010). Other noteworthy 
differences in canine OS include, the median age of onset, which occurs in adulthood in dogs. 
This is different from pediatric OS where adolescents are most commonly affected.  In addition, 
physeal plates in dogs (versus children) are closed at the age of onset of OS in the breeds of dogs 
that are over-represented for OS development (Fan, 2010; Withrow and Wilkins, 2010). Despite 
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these differences, the biology and genetics of OS are highly conserved between people and dogs 
(Paoloni et al., 2009).  Importantly, the canine OS model includes spontaneous and natural 
development of the primary tumor and pulmonary metastases within an immunocompetent host, 
thus the dog serves as a valuable comparative model for OS. A newly formed National Cancer 
Institute (NCI)-initiated consortium, the Comparative Oncology Trials Consortium (COTC), has 
integrated preclinical studies in dogs with naturally occurring OS with the drug development 
process. The COTC has developed a canine OS biospecimen repository. This national 
biospecimen repository seeks to collect cancer, normal tissues, and biofluids from 3000 dogs in 
an effort to coordinate the generation of biological tools for use in canine cancer that will 
identify agents with the greatest potential to improve outcome and prioritize those agents for 
early human clinical trials. 
Currently, the most conventional experimental system used to study OS biology is 
syngeneic (genetically identical or closely related, so as to allow tissue transplant), orthotopic (in 
the correct anatomical site) transplantation mouse models. Conditional knockout and orthotopic, 
transplantable, mouse models provide an experimental system to model the genetics of human 
osteosarcoma. These models have proven very useful in identifying regulatory pathways in OS 
tumorigenesis and metastatic progression as well as, providing a valuable platform for 
developing novel therapeutic strategies. While the etiology of OS is unknown, it is evident that 
tumor suppressor genes p53 and Rb (retinoblastoma) play a role, as children with familial 
mutation syndromes affecting either of these genes have higher incidences of OS (Hansen, 
1991). Conditional knockout mice represent an experimental system that supports endogenous, 
spontaneous generation of OS through knockouts of critical tumor suppressor genes. These 
models more closely simulate the process of primary tumorigenesis and provide an opportunity 
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to study early steps of the metastatic cascade. For example, genetically engineered mice (GEMs) 
lacking the p53 and Rb genes readily develop OS; however, while p53 loss is associated with the 
development of OS, the Rb gene mutation, acting synergistically with p53 is not sufficient to 
induce osteosarcomagenesis (Berman et al., 2008; Walkley et al., 2008). Orthotopic, 
transplantable, spontaneous metastasis mouse models offer another opportunity to study 
metastasis.  These models provide a more accurate depiction of metastatic progression as 
individual tumor cells derived from the primary bone lesion must successfully establish distant 
metastases similar to that naturally occuring in OS in humans. A potential limitation of  using a 
xenogeneic (derived or obtained from an organism of a different species as a tissue graft) model 
in which human OS cells are introduced into immunodeficient mice, rather than a murine 
syngeneic model system is that the xenogeneic model cannot mimic the host microenvironment 
and tumor cell interactions that naturally occur in humans with OS (Fan, 2010). 
 
Metastasis  
As suggested above, the single most significant negative prognostic factor in the 
treatment of cancer is the dissemination of cancer cells and the formation of metastatic disease 
rather than the primary tumor.  The primary research need in the field is to understand the 
biology of metastasis in osteosarcoma, to improve outcomes for future patients.   
There is evidence to suggest that the first stages of metastasis can be an early event 
(Schmidt-Kittler et al., 2003) and that in many patients the metastatic process has been initiated 
by the time of diagnosis.  Emblematic of the problem is the clinical progression seen in most 
patients with OS.  In spite of the prevalence of pulmonary metastases in OS patients, metastasis 
is an extremely inefficient process. Dissemination of cancer may occur through one of three 
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pathways: (1) direct seeding of body cavities or surfaces, (2) lymphatic spread, and (3) 
hematogenous spread (Kumar et al., 2005; Slauson and Cooper, 2002).   Hematogenous spread is 
typical of solid tumors such as OS. The metastatic cascade is an extremely complex multistage 
process.  In order for a metastatic lesion to become clinically detectable, it must successfully 
complete a sequential series of steps of the cascade.  Within this process, each step is subject to a 
wide variety of influences; thus, at any point in the sequence the tumor cells may not survive.  
Failure to complete any step results in failure to colonize a distant site. The metastatic cascade 
can be divided into two phases: (1) invasion of the extracellular matrix (ECM) and (2) vascular 
dissemination and arrest in a distant site (Kumar et al., 2005).   Prior to invasion of the 
extracellular matrix, clonal expansion, growth, diversification, and angiogenesis must occur to 
produce metastatic subclones within the primary tumor (Krishnan et al., 2006).  These 
“transformed” tumor cells must then separate from the primary tumor and interact with the ECM 
at several stages in the metastatic cascade.  In order for the neoplastic cells to breach the 
underlying basement membrane they must first detach themselves from one another and their 
surroundings.  After the cells are detached, it is necessary for them to attach to matrix 
components (e.g., laminin, collagen, and fibronectin) so that the basement membrane can be 
enzymatically degraded to create passageways for tumor cell migration (Slauson and Cooper, 
2002).  The basement membrane is degraded by serine, cysteine, and matrix metalloproteinases 
(MMPs).  Loss of either cell-cell or cell-matrix interaction activates caspase proteases, the 
hallmark of apoptosis (Frisch and Francis, 1994).  Tumor cells resist detachment-induced 
apoptosis (anoikis) by establishing contacts with other tumor cells (homotypic interactions) or 
with host cells like platelets and inflammatory cells (heterotypic interactions).  Both types of 
interactions generate intracellular signals that prevent anoikis (Grossmann, 2002; Krishnan et al., 
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2006).   Also, there can be overexpression of essential proteins by cancer cells that directly 
inhibit anoikis.  For example, TrkB, a tyrosine kinase receptor (Douma et al., 2004), the integrin 
pair α2β3 (Ruoslahti and Reed, 1994), adenomatous polyposis coli (APC) gene product (Beavon, 
2000), focal adhesion kinase, galectin-3, and transforming growth factor-β (Krishnan et al., 
2006) are reportedly involved in resistance to anoikis.    
Once tumor cells have invaded the surrounding tissues and migrated through the 
basement membranes into the bloodstream (lymphatics or peritoneal space), they are susceptible 
to destruction by innate and adaptive immune defenses.  In addition, destruction of intravasated 
tumor cells by hemodynamic forces and shearing is thought to contribute to metastatic 
inefficiency (Weiss, 1992). However, it has been demonstrated recently that some tumor cells in 
the bloodstream can arrest in capillary beds and extravasate with high efficiency (Luzzi, 1998). 
Neoplastic cells must strategically evade detection and destruction by the immune system and 
other antitumor effectors at all stages of metastatic progression (Hunter, 2004; Krishnan et al., 
2006; Krishnan et al., 2005; Kumar et al., 2005; Slauson and Cooper, 2002).  Adhesion among 
tumor cells along with adhesion between tumor cells and platelets allow tumor cells to aggregate 
in clumps (tumor emboli) within the bloodstream (Kumar et al., 2005).  These tumor-platelet 
aggregates may enhance tumor cell survival and implantation.  Arrest and extravasation of tumor 
emboli at distant sites involve adhesion to the endothelium followed by exit through the 
basement membrane.  Involved in this process are adhesion molecules such as integrins and 
laminin receptors and previously mentioned proteolytic enzymes (Slauson and Cooper, 2002).  
At the new site, the tumor cells need to survive, proliferate, develop a vascular supply, and avoid 
and survive apoptotic signals and host immune responses.  The site at which the circulating 
tumor cells leave the capillaries to form secondary deposits is defined, in part, by the anatomic 
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location of the primary tumor and associated venous drainage (Kumar et al., 2005)  However, 
there are many observations that suggest the natural drainage pathways do not fully explain the 
distribution of metastasis.  Others have demonstrated that there is a tendency for the first 
capillary bed encountered as the primary site of metastases (Weiss, 1988). Currently, it is 
believed that the specific site for distant metastasis is not simply due to an anatomic location, the 
primary tumor, or proximity to secondary sites but rather involves interactions between tumor 
cells and the local microenvironment at the secondary site. One theory that attempts to explain 
the selectivity of certain tumor types to metastasize to specific organ sites, for example 
osteosarcoma to lung and bone, is the “seed and soil hypothesis” first proposed in 1889 by the 
surgeon Stephen Paget and then experimentally tested by Fidler in the 1980s (Hart and Fiddler, 
1980; Paget, 1889).  Paget hypothesized that communication between the cancer cell (seed) and 
the target organ (soil) via molecular interactions resulted in nonrandom selection of target organs 
by the cancer cells.  Modulation of the tumor microenvironment (soil) by the tumor cell (seed) is 
a critical determinant of survival of metastatic cells (Paget, 1889).  Alternatively, others have 
suggested that target organ tropism is based on vascular access and proximity.  For example, 
arteries are less readily penetrated than veins due to their thicker walls, however, arterial spread 
may occur when tumor cells pass through the pulmonary capillary bed or when pulmonary 
metastases give rise to additional tumor emboli.  With venous invasion, neoplastic cells follow 
the venous flow draining the site of the tumor; hence, the liver and lungs are most frequently 
involved secondarily in hematogenous dissemination (Kumar et al., 2005).  It is important to 
note however that venous drainage alone does not define the sites of metastasis. Mendoza and 
Khanna (2009), recently suggested in their review of cancer metastasis that a critical outcome of 
the seed-soil interaction is resistance to the stresses tumor cells encounter that would otherwise 
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impede metastatic progression. The final critical step in the development of metastasis is the 
generation of a new blood supply (angiogenesis).  Proliferation of endothelial cells is a rigidly 
controlled balance between proangiogenic factors (e.g., VEGF, fibroblast growth factor, and IL-
8) and their antagonists (e.g., thrombospondin-1, maspin, and angiostatin) (Krishnan et al., 2006; 
Krishnan et al., 2005; Kumar et al., 2005; Slauson and Cooper, 2002).  In cancer, this balance is 
shifted toward proangiogenic factors.   
 
Metastasis and stress 
 One of the most critical determinants of a tumor cell’s success in metastasis may be its 
ability to resist the stresses that are associated with progression through the metastatic cascade 
and survival at secondary sites. Stresses including low oxygen tension (hypoxia), reactive 
species, inflammation, nutrient deprivation, and pH can challenge the growth and progression of 
a tumor cell and are usually initially detrimental to the tumor cell’s survival. However, it is 
believed that such stresses may also provide a selective pressure favoring growth of more 
metastatically ‘fit’ cells (Witz, 2006). The mammalian target of rapamycin (mTOR) is a central 
regulator of cell growth, proliferation, survival, and metabolism.  It exists in two distinct 
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Guertin, 2007). 
mTORC1 is a critical mediator of the cellular response to many stresses including genotoxic, 
nutrient, energy, and oxygen-related stresses. mTORC1 regulates the translational machinery 
activity as a whole and controls the translation of a subset of mRNAs that promote cell growth 
and proliferation (Sengupta, 2010). Major downstream effectors of mTORC1 include regulators 
of protein translation initiation and cell growth, ribosomal subunit S6 kinase 1 (S6K1) and 
eukaryotic initiation factor 4E binding protein 1 (4E-BP1). Dephosphorylation of the 4E-BPs 
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inhibits cap-dependent translation initiation by binding and sequestering eukaryotic initiation 
factor 4E (eIF4E) and preventing its assembly into the eukaryotic initiation factor 4F (eIF4F) 
cap-binding complex (Pause, 1994).         
 
Translation and translation initiation in cancer/metastasis 
There is now a growing body of evidence that suggests links between dysregulation of 
protein synthesis and malignant progression of cancer.  Clemens and Bommer (1999) discuss the 
many ways in which translational control is relevant to the topic of cancer including how the 
efficient expression of important proteins involved in cell growth regulation, proliferation, or cell 
death may be controlled at the translational level by changes in the activity of components of the 
protein synthesis machinery.  Also, mutations that lead to changes in the structure of individual 
mRNAs may alter the rates at which the proteins encoded by these mRNAs are produced.  
Finally, disruptions in the regulation of signaling pathways that result in a loss of control of the 
synthesis of growth-promoting proteins (or impair the synthesis of growth-inhibitory or pro-
apoptotic proteins) may alter the balance of production of important cellular components 
(Clemens and Bommer, 1999).   
Translation is the second process of protein biosynthesis, which is part of the overall 
process of gene expression. In translation, mRNA is decoded to produce a polypeptide based on 
the genetic code.  The process converts an mRNA sequence into a chain of amino acids that form 
a protein (Lehninger et al., 1993).  The mRNA carries genetic information encoded as a 
ribonucleotide sequence from the chromosomes to the ribosomes.  The ribonucleotides are read 
by translational machinery.  The ribosome is a multisubunit structure containing ribosomal RNA 
(rRNA) and proteins (Lehninger et al., 1993) and is described as the “factory” where amino 
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acids are assembled into proteins. There are three distinct phases of translation including 
initiation, elongation, and termination.  In order for translation to proceed there must first be 
activation.  In activation, the correct amino acid is joined to the correct transfer RNA (tRNA).  
When the tRNA has an amino acid linked to it, it is termed “charged”.  Once the tRNA has been 
charged, initiation can begin (Lehninger et al., 1993; Pain, 1996).  Initiation involves the small 
subunit of the ribosome binding to the 5’ end of mRNA with the help of other proteins that assist 
the process (initiation factors;IFs) (Pain, 1996).  Elongation takes place when the next charged 
tRNA in line binds to the ribosome along with GTP and an elongation factor (EF).  Termination 
of the polypeptide happens when the A site of the ribosome faces a stop codon (Pain, 1996).  Of 
the three phases, initiation is the most important as it is considered to be rate-limiting in the 
translation process.  Cap-dependent translation initiation is the major translation initiation 
pathway in eukaryotes.  All eukaryotic mRNAs present a 5' terminal nuclear modification, the 
cap structure (Gingras et al., 1999).  In translation, the cap structure marks the spot where the 
small ribosomal subunit (40S) is to be recruited.  Important in this recruitment process is the 
eukaryotic initiation factor 4F (eIF4F) complex.  eIF4F is a 3-subunit complex composed of 
eIF4E, eIF4A, and eIF4G  (Gingras et al., 1999; Mamane et al., 2004).  eIF4G is a scaffolding 
protein that brings together eIF4F, as it has two binding sites for eIF4A and one binding site for 
eIF4E, but more importantly, it bridges the mRNA cap (via eIF4E) and the 40S ribosomal 
subunit (via eIF3) (Gingras et al., 1999; Mamane et al., 2004).  eIF3 is associated with the small 
ribosomal subunit, and plays a role in preventing the large ribosomal subunit from binding 
prematurely (Fig. 2.1).   eIF4A is an ATP-dependent RNA helicase.  Finally, eIF4E is the cap-
binding protein, which is a critical node in RNA regulation impacting  
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Figure 2.1. Translational Machinery. Under physiologic conditions, eIF4E is bound to its 
inhibitory binding protein, 4EBP1. Upon phosphorylation (P) of 4EBP1, eIF4E is liberated 
from 4EBP1 and able to bind with capped mRNA (7mG) and eIF4G-eIF3-eIF4A subunits, 
forming the eIF4F complex. eIF4E is the rate-limiting component of the eIF4F complex. 
eIF4F is a necessary component of the 48S initiation complex. PABP = poly(A) binding 
protein. 
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nearly every stage of cell cycle progression (Mamane et al., 2004) Specifically, eIF4E 
coordinately promotes the mRNA export of several genes involved in the cell cycle. 
 A model describing a hierarchy of weakly and strongly translated proteins in cells has 
emerged (Baserga, 1990; Graff and Zimmer, 2003). These proteins are differentially regulated by 
translation.  The “strongly translated” proteins are a stable set of “less regulated” proteins with 
short, unstructured 5’ untranslated regions (UTRs) that are expressed at a basal rate with limited 
input from external stimuli.  In contrast, “weakly translated” proteins typically have lengthy, G-C 
rich, highly structured 5’UTRs and are maintained as stable mRNA transcripts.  These so-called 
weakly translated proteins are not translated unless the translational machinery is upregulated by 
stimuli such as growth factors or cellular stress (Bjornsti and Houghton, 2004; De Benedetti and 
Graff, 2004; Sonenberg and Dever, 2003).  This hierarchy of proteins provides efficiency in 
biological systems by eliminating the need for indiscriminate, large-scale translation of all 
proteins at all times and locations in the cell.  The model of weakly and strongly translated 
proteins suggests that, under specific signals and requirements, specific proteins can be translated 
and delivered to specialized locations in the cell (Richter and Sonenberg, 2005). For example, 
when the cell is exposed to stress or growth factors, there is an increased concentration of 
unbound (free) eIF4E available to bind with the eIF4F complex creating the specifically 
enhanced translation initiation that the weakly translated proteins require for efficient translation.  
The end result is disproportionately enhanced translation of weak proteins (De Benedetti and 
Graff, 2004).  Interestingly, several mRNAs with complexity (lengthy, G-C rich, highly 
structured) in the 5’ UTR (weakly translated proteins) have been associated with cancer (Table 
2.1), including FGF-2 (Nathan et al., 1997a), VEGF (Scott et al., 1998), c-myc (Saito et al., 
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1983), and cyclin-D1 (Stacey, 2003). Additionally, there are many proto-oncogenes that are 
regulated at the translational level including c-myc, c-fos, and c-jun (De Benedetti and Graff, 
2004; Mamane et al., 2004). 
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Table 2.1. Cap-dependent metastasis-associated mRNAs 
 
Function      Metastasis-related gene  
 
Cell proliferation     c-Myc 
       CDK2 
       cyclin D1 
ODC 
 
Angiogenesis      VEGF 
       FGF2 
PDGF 
 
Anti-apoptotic      Mcl-1 
       Bcl-2 
       Bcl-xL 
       survivin 
 
Invasion      MMP 9 
       heparanase 
 
CDK2 = cyclin-dependent kinase 2, ODC = ornithine decarboxylase, VEGF = vascular endothelial growth factor, 
FGF2 = fibroblast growth factor 2, PDGF = platelet derived growth factor, Mcl-1 = Induced myeloid leukemia cell 
differentiation protein Mcl-1, Bcl-2 = B cell lymphoma 2, Bcl-xL = B lymphoma x isoform long, MMP9 = matrix 
metalloproteinase 9 
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eIF4E 
Eukaryotic initiation factor 4E (eIF4E) is a 25 kDa mRNA cap-binding phosphoprotein 
(Rhoads et al., 1993; Sonenburg and Gingras, 1998).  eIF4E is an important modulator of cell 
growth and proliferation.  It is the least abundant component of the translation initiation 
machinery (Rhoads et al., 1993).  Within translation initiation, the abundance and activation of 
eIF4E is considered both rate and process limiting (Rhoads et al., 1993; Sonenburg and Gingras, 
1998).  The activity of eIF4E is modulated by phosphorylation and its interaction with eIF4E-
binding proteins (4EBPs) (Flynn and Proud, 1996; Raught and Gingras, 1999).  Under normal 
cellular conditions, eIF4E is bound by inhibitory 4EBPs.  These 4EBPs block eIF4E from 
interaction with eIF4G, preventing the assembly of the eIF4F complex.  Extracellular stimuli 
such as growth factors, hormones, mitogens, amino acids, cytokines and G-protein coupled 
receptor agonists induce 4EBP phosphorylation at multiple sites as a consequence of both the 
ras-ERK and PI3 kinase/AKT pathways (Gingras, 2001; Gingras et al., 1999).  Phosphorylation 
dislodges the inhibitory 4EBPs from eIF4E enabling it to deliver mRNAs effectively to the 
eIF4F complex and facilitating translation by the eIF4F complex (Raught and Gingras, 1999).  
The following mechanisms are capable of increasing levels of free eIF4E: (1) increased eIF4E 
expression, (2) decreased 4EBP expression, or (3) increased 4EBP phosphorylation (Huang et 
al., 2003).  It has been suggested that cancer cells have elevated free eIF4E, resulting from 
phosphorylation of 4EBPs, and reduced expression of the 4EBPs (Graff and Zimmer, 2003).  
Continual high levels of eIF4E results in disproportionately enhanced translation of weak 
mRNAs.  Since many of these weak mRNAs encode growth regulation proteins, their 
upregulation may enable tumorigenesis and ultimately metastatic progression (De Benedetti and 
Graff, 2004; Graff and Zimmer, 2003).     
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Numerous studies have now implicated eIF4E in tumor formation and, potentially, 
metastatic progression.  Overexpression of eIF4E in cell lines, NIH3T3, CREF, and MM3MG 
has resulted in cellular transformation and tumorigenesis (De Benedetti et al., 1994; De 
Benedetti and Rhoads, 1990; Lazaris-Karatzas et al., 1990; Li et al., 2001).  Antisense RNA-
mediated suppression of eIF4E suppressed proliferation and changed cell morphology in HeLa 
cells (De Benedetti and Rhoads, 1990) and suppressed soft-agar colonization as well as tumor 
formation and growth in ras-transformed CREF cells (Rinker-Schaeffer et al., 1993).  
Furthermore, the ability of the ras-transformed CREF cells to invade surrounding normal tissues 
and metastasize was markedly reduced as well (Graff et al., 1995). Expression of antisense RNA 
to eIF4E in human breast, head and neck cancer cell lines suppressed tumor formation and 
angiogenesis (DeFatta et al., 2000; Nathan et al., 1997a; Nathan et al., 1997b).  Finally, 
functional blockage of eIF4E by expressing 4EBPs can revert the transformed and tumorigenic 
phenotype (Rousseau et al., 1996).   Overexpression of eIF4E has been documented in human 
carcinomas of the breast (De Benedetti and Graff, 2004; Kerekatte et al., 1995; Scott et al., 
1998), head and neck (Franklin et al., 1999; Nathan et al., 1997b), bladder (Crew et al., 2000), 
cervix (Matthews-Greer et al., 2005), lung (Rosenwald et al., 2001; Seki et al., 2002), prostate 
(Graff, 2009), colon and rectum (Berkel et al., 2001; Rosenwald et al., 1999), as well as in non-
Hodgkin’s lymphomas (Wang et al., 1999) when compared with normal tissues and benign 
lesions. Collectively these data suggest that eIF4E may play a key role in both tumor formation 
and metastatic progression by specifically enhancing the translation of a subset of key genes 
(weakly translated proteins) necessary for overriding normal growth constraints (c-myc, cyclin 
D1), inducing angiogenesis (VEGF, FGF-2), and facilitating tumor invasion and metastasis 
(MMP-9, heparanase) (Jiang and Muschel, 2002; Yang et al., 2003; Zimmer et al., 2000).  eIF4E 
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enables cells to efficiently coordinate the translation of these needed transcripts during metastatic 
progression, thus increasing success in the demanding process of metastasis. While there has 
been a wealth of evidence in both experimental cancer models and in human cancer tissues 
implicating eIF4E in tumor development and progression, the majority of this work has been 
conducted in epithelial tumors and mouse fibroblast cells.  Expression and activity of eIF4E in 
mesenchymal tumors, particularly osteosarcoma, have not been reported.  
A clearer understanding of metastasis biology is required to improve cancer mortality, 
especially in osteosarcoma patients. In addition, a better understanding would allow development 
of novel therapeutic strategies to prevent growth of metastases. One opportunity for improved 
translational research is the comparative oncology approach. Cross-species comparisons in OS 
assist in establishing a better biological understanding of the complexity of the metastatic 
cascade in OS. The comparative perspective across species lines can also facilitate the discovery 
of novel targets for treatment. This is essential, as the development of pulmonary metastases in 
OS patients remains the most common cause of death. Less than 30% of patients that present 
with metastatic disease at the time of diagnosis will survive. Unlike most other cancers, in OS, 
when possible, the resection of pulmonary metastatic nodules is the first line of treatment in 
recurrence.  Furthermore, the resistance of these pulmonary metastases to currently available 
therapy is common. As such, new treatments are needed. A review by Khanna (2008) 
summarizes novel therapeutic targets under discovery and development for OS. Advances in the 
basic scientific understanding of three common clinical features of the disease have uncovered 
new targets based on the following: (1) the origin of osteosarcoma (bone or mesenchymal cells), 
(2) the metastatic process, and (3) the metastatic lung lesion (Khanna, 2008). Prioritization of 
these targets for pre-clinical and clinical trials have shown promise for improving outcomes in 
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the OS patients who fail conventional treatment. A comparative perspective on the problem of 
OS metastasis that utilizes a cross-species approach may offer unique opportunities to assist in 
this prioritization and generate new hypotheses related to this important clinical problem.  
We believe that opportunities to improve outcomes for patients who present with 
metastases and those at risk for metastatic progression require an improved understanding of 
tumor biology and metastasis. The primary research need in the field is to understand the biology 
of metastasis in OS. The complexity of metastasis remains an enigma and therefore demands a 
focus on new tools and reagents in order to explore new hypotheses in the field. In our laboratory 
we have utilized new tools (human osteosarcoma tissue microarray (TMA)) and designed new 
reagents (ex vivo pulmonary metastasis assay (PuMA)) in an attempt to help elucidate the 
underlying steps involved in tumor dissemination, colonization, and metastatic progression. To 
build on our understanding of metastasis biology, we designed and constructed a robust 
outcome-linked TMA to compliment other TMAs currently available and address the limitation 
of small sample size while providing a wider variety of sample types that characterize the disease 
including pre-treatment excisional biopsies, post-treatment definitive resections, and lung 
metastases. We have used our TMA to detect and validate protein biomarkers, including eIF4E, 
across a variety of patients. In addition, we have further developed mechanisms to view 
metastasis at the single cell level through the design of a simple, ex vivo, image-based, PuMA 
that allows real-time assessment of metastatic progression of GFP-expressing tumor cells in a 
relevant tumor microenvironment. We have used the PuMA to evaluate novel therapeutics that 
specifically target metastatic progression and metastatic lesions in OS in a timely manner. Also, 
the PuMA faithfully predicted high- and low-metastatic phenotypes of human and mouse cancer 
cell lines and the clonally related variants with greater metastatic propensity in vivo were also 
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associated with greater metastatic phenotype in the PuMA. These tools will advance our 
understanding of both OS metastasis biology and therapeutic strategies. 
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Chapter 3. Evaluation of eIF4E Expression in an Osteosarcoma Specific 
Tissue Microarray 
 
ABSTRACT 
The ability to define osteosarcoma (OS) patients at greatest risk for metastatic progression and 
non-responsiveness to conventional therapy is currently not possible.  Such biomarkers are 
needed to predict overall prognosis, probability of metastases at diagnosis, and response to 
chemotherapy.  The tissue microarray (TMA) serves as a powerful tool for detecting and 
validating protein biomarkers across a variety of patients.  We constructed a novel outcome-
linked TMA to add to and address shortcomings of currently available osteosarcoma tissue 
resources. To test the utility of our TMA we surveyed the expression of eukaryotic initiation 
factor 4E (eIF4E) in osteosarcoma patients using immunohistochemistry. Aberrant regulation of 
translation initiation is a feature of many cancers. eIF4E is central to initiation of protein 
synthesis. Its expression and activity have been implicated in tumor formation and potentially 
malignant and/or metastatic progression in some carcinomas. We found that eIF4E was 
uniformly expressed in osteosarcoma patient samples. No association was found between eIF4E 
and outcome in osteosarcoma patients. This novel osteosarcoma TMA provided a facile 
mechanism to assess the role of a relevant protein biomarker in osteosarcoma. 
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INTRODUCTION 
Osteosarcoma is the most common primary malignancy of bone. Approximately 400 new 
cases of osteosarcoma are diagnosed in pediatric patients in the United States each year 
(American Cancer Society, http://www.cancer.org/docroot/home/index.asp). For most pediatric 
osteosarcoma patients, despite successful management of the primary tumor and multi-agent 
adjuvant therapy, the development of metastases, commonly to the lung, is the most common 
cause of death. Opportunities to improve outcomes for patients who present with metastases and 
those at-risk for metastatic progression requires an improved understanding of tumor biology.  
Defining patients at the greatest risk for metastatic progression and non-responsiveness to 
conventional therapy is not currently possible.  Such prospective identification of patients at 
highest risk would allow the use of novel therapeutic agents in patients at greatest need. The 
definition and or validation of biomarkers that predict outcome requires readily available patient 
samples that are linked to complete clinical follow-up.  Tissue microarrays (TMAs) are well-
recognized, widely used tools that enable rapid analysis of large patient cohorts for the 
expression of protein biomarkers using archival paraffin-embedded samples.  To enable 
biomarker and target evaluation in osteosarcoma we report herein on the development of an 
outcome-linked osteosarcoma TMA available as a community resource.  The tissue array is 
available through the National Cancer Institute (http://ttc.nci.nih.gov/forms/).  As an example of 
the utility of the TMA, we asked if the expression of eukaryotic initiation factor 4E (eIF4E) was 
linked to cancer progression. eIF4E is a 25 kDa cytosolic protein that binds to the 7-methyl 
gaunosine cap at the 5’ UTR of cellular mRNAs during translation initiation. Since eIF4E is 
found in much lower concentrations than other translation initiation factors, it is the rate-limiting 
component in translation initiation (Rhoads et al., 1993; Sonenburg and Gingras, 1998). eIF4E is 
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an important modulator of cell growth and proliferation and is overexpressed in a number of 
malignancies including lymphomas, cancers of the breast, lung, head and neck, bladder, prostate, 
colon and rectum, esophagus, skin, and cervix (De Benedetti and Graff, 2004; Matthews-Greer, 
2005; Salehi, 2006; Salehi, 2007; Sonenburg and Gingras, 1998).   Here, we asked (i) if eIF4E is 
expressed in osteosarcoma tissues and (ii) whether the expression levels of eIF4E are linked to 
clinical outcome in these patients. 
We report the results of TMA immunohistochemical expression profiling of eIF4E in a 
variety of osteosarcoma sample types including pre-treatment excisional biopsies, post-treatment 
definitive resections, and lung metastases.  We found eIF4E to be similarly expressed in all 
osteosarcoma sample subtypes.    
 
MATERIALS AND METHODS 
Patient Selection and Pathology 
Patient records from 75 osteosarcoma patients (35 males and 40 females) linked to 89 
samples (collected between 1984 and 2001) and 12 control tissues (formalin-fixed paraffin-
embedded blocks) were provided by the Montefiore Hospital, Memorial Sloan Kettering Cancer 
Center, and Center for Cancer Research for the development of the osteosarcoma tissue array.  
Specimens were collected from the extremities, pelvis, and craniofacial bones. Written informed 
consent in accordance with the Ethics Committee and Institutional Review Board of the 
Memorial Sloan Kettering Cancer Center and/or Montefiore Hospital was obtained prior to tissue 
procurement. Using these tissues and associated clinical annotation a schema of tissue cores, 
arranged according to the sample type (biopsy, definitive resection, or resection of distant 
metastasis) was developed. Primary biopsy specimens were those taken at the time of patient 
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diagnosis prior to chemotherapy treatment.  Definitive resection specimens were taken following 
neo-adjuvant chemotherapy at the time of definitive surgical treatment and metastatic specimens 
were collected at the time of relapse.  All of the metastatic specimens included on the tissue array 
were taken from the lung. Diagnosis of osteosarcoma was confirmed by histologic review of 
hematoxylin and eosin (H&E) stained slides.  For our purposes, clinical outcome was defined as 
overall survival of the patient. Occasionally, multiple specimens were taken from the same 
patient, for example, four primary biopsy patients also had definitive resection samples and two 
definitive resection patients had metastases at presentation. Final patient specimens included: 21 
primary biopsies (19 patients), 48 definitive resections (47 patients), 20 metastases (14 patients), 
and 12 control tissues (Fig. 3.1). 
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Figure 3.1. Osteosarcoma Tissue Microarray. Low magnification (0.3X) of human 
osteosarcoma specimens stained with H&E. Tissue microarray contains 111 tissue cores. Final 
patient specimens included 21 pre-treatment biopsies (19 patients), 48 post- treatment definitive 
resections (47 patients), 20 lung metastases (14 patients), and 12 control tissues. A liver 
specimen is placed in the upper left hand corner of the TMA in order to verify proper 
orientation. 
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Construction of the Osteosarcoma Tissue Microarray  
The physical construction of the TMA followed the guidelines previously used by the 
National Cancer Institute’s Tissue Array Project 
(http://ccr.cancer.gov/tech_initiatives/tarp/default.asp). Each individual case was represented by 
1 tumor core of 1 mm that was taken from the original paraffin block. The TMA block contained 
89 osteosarcoma specimens and 12 control tissues including liver, kidney, testis, muscle, lymph 
node, normal bone, placenta, bone cyst, fibrosarcoma, pleomorphic liposarcoma, and malignant 
fibrous histiocytomas. Serial 5 µm sections were cut from the TMA block and used for 
immunohistochemical analysis.  
 
Immunohistochemistry 
We have previously reported methods for immunohistochemical staining of TMAs 
(Hewitt, 2004). Briefly, primary rabbit polyclonal anti-eIF4E-antibody (Cell Signaling 
Technology, Danvers, MA) was applied to the TMA at a dilution of 1:100.  Substitution of non-
immune serum for the primary antibody was used for negative control incubations. Liver and 
lymph node cores were used as positive controls for eIF4E staining.  Slides were developed with 
avidin-biotin complex kit (DAKO, Carpinteria, CA) and counterstained with hematoxylin 
(DAKO).  
 
Scoring of the TMA 
Before scoring, tissue cores containing less than 10% of the original tissue (3 tissue 
cores) or those containing less than 5% tumor cells (8 tissue cores) were excluded from the 
analysis. Scoring was based on staining intensity (Fig. 3.2B).  The intensity of the signal was 
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scored as 0 (no expression), 1 (mild expression), 2 (moderate expression) or 3 (marked 
expression). All tissue cores were co-scored independently by two independent readers who were 
blinded to the clinical information. Staining intensity was based on tinctorial differences in 
cytoplasmic immunoreactivity. If there was disagreement about scores, the tissue cores were 
reviewed together and a consensus score was reached.  
 
Clinical Outcome Measures 
The clinical endpoint of this study was overall survival (Fig. 3.3A).  Overall survival was 
defined as the time from diagnosis until death or last patient contact.  Staining results were 
compared to overall survival (Fig. 3.3B). 
 
Statistical Analyses 
Descriptors of eIF4E staining intensities, including mean, median, confidence intervals, 
and log-rank tests were determined using Microsoft Excel and GraphPad Prism version 4c for 
Macintosh software. Log-rank and log-rank trend statistics were used for assessment of survival 
curves.  A P value less than 0.05 was considered significant. 
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Figure 3.2. (A) Expression of eIF4E in all osteosarcoma patients. eIF4E is expressed in 
most osteosarcoma samples and the majority of samples have a staining intensity score of 1 
or 2. (B) Representative tissue cores of osteosarcoma immunoreactivity for eIF4E. Scoring 
was based on tinctorial differences in staining intensities (i.e., 0, 1, 2, and 3) of the tissue 
cores. 
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Figure 3.3. Kaplan-Meier survival curves. (A) Five-year survival rate for patients represented in the 
TMA with localized osteosarcoma without clinically detectable metastases is approximately 75%. 
(B) Kaplan-Meier survival analysis showed no significant differences in survival among distinct 
eIF4E staining intensities (P = 0.1821). Therefore, there is no correlation between eIF4E expression 
and overall survival in osteosarcoma patients with localized disease. 
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RESULTS 
 
TMA Patient Characteristics 
 Sixty-seven percent of samples were taken from patients 21 years of age or less (mean-
14.5, median-15).  Thirty-three percent of samples included patients that were older than 21 
years (mean-43.3, median-37). Specimens included tissues collected at biopsy (n=21), during 
definitive resection of the tumor (n=48), and during resection of distant metastasis to the lung 
(n=20) for a total of 89 specimens.  A variety of anatomic sites and histologic subtypes (Table 
3.1) were included.  The majority of tumors were high-grade (47 of 48 patients; 98%) 
chondroblastic osteosarcomas (14 of 43 patients; 33%) that were located in the femur (20 of 52 
patients; 38%).  Nine patients had lung metastases at the time of diagnosis.  One patient had a 
low-grade osteosarcoma of the metatarsus. Following procurement, samples of all specimens 
were decalcified, formalin-fixed, and paraffin embedded.   
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TABLE 3.1. Patient Characteristics 
 
     Number of Patients 
 
Gender 
Females     40 
Males      35       
 
Age (years) 
≤ 21       50 
≥ 21       25 
 
Sample Types 
Pre-treatment biopsies  19a 
Post-treatment definitive resections  47b 
Lung metastases    14 
 
Anatomic Location 
Femur      20 
Proximal tibia     11 
Humerus       6 
Pelvis        5 
Craniofacial bones      4 
Metatarsal       2 
Extraskeletal       2 
Ulna        1 
Knee        1 
Not Specified     22 
 
Histologic Subtype    
Osteoblastic     11 
Chondroblastic    14  
Fibroblastic       4 
Giant cell rich       4 
Mixed      10 
Not Specified     31 
 
 
a Four pre-treatment biopsy patients also had post-treatment definitive resection samples  
b Two post-treatment definitive resection patients had lung metastases at presentation 
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eIF4E expression and relationship with overall survival in osteosarcoma patients  
To assess the utility of our TMA and test a hypothesis of interest in our studies of 
osteosarcoma biology, the expression of eIF4E in osteosarcoma tissues was surveyed using 
immunohistochemistry. Tissue controls (positive controls; liver and lymph node) exhibited 
diffuse cytoplasmic expression of eIF4E with staining intensities ranging from mild to marked. 
An assessment for eIF4E was possible in the TMA for 78 of 89 cores. Positive osteosarcoma 
immunoreactivity for eIF4E was detected in 71 of 78 (91%) tumors analyzed. Diffuse, mild 
(intensity score 1) to moderate (intensity score 2) cytoplasmic expression was observed in 67 of 
78 (86%) specimens. Specifically, eIF4E was expressed in 15 of 17 (88%) primary biopsy 
samples, in 40 of 44 (91%) definitive resections, and in 17 of 17 (100%) metastatic lesions (Fig. 
3.2A). Kaplan-Meier survival curves were used to examine differences in overall survival 
between each defined staining intensity (quartiles) and between high and low eIF4E expressers 
(Fig. 3.3B). Based on the uniform expression of eIF4E in most patient samples, it was not 
surprising to find that the expression intensity of eIF4E protein alone was not an independent 
predictor of overall survival (P = 0.1821) (Fig. 3.3B).  
 
DISCUSSION 
Successful management of primary tumors and advances in multimodal chemotherapy 
regimens have improved the overall 5-year relapse-free survival rate from 20% to approximately 
60-70% for osteosarcoma patients who present with localized disease (Meyers, 2009). However, 
long-term outcomes for patients have not substantively improved over the last 20 years despite 
intensification of therapy before, during, and after the management of the primary tumor.  
Furthermore, the 5-year survival for patients who present with metastatic disease is 10-30% and 
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has remained static over this time period (Meyers, 2009). The importance of defining patients 
with the poorest outcomes at the time of diagnosis is critical for improvements to be seen in this 
disease.  Unfortunately, the biological heterogeneity of this disease, coupled with the relative 
rarity of the cancer and limited availability of outcome-linked patient data, has made such 
advances difficult.  TMAs are well-recognized tools that play an important role in the evaluation 
of biological targets in tumors.  The value of TMAs in the study of rare cancers is further 
amplified.  Currently, there are six osteosarcoma TMAs reported in the literature that are 
consistently used within the research community (Table 3.2) (Di Cristofano et al., 2010; Do et 
al., 2008; Folio et al., 2009; Kim et al., 2007; Salas et al., 2009; Somers et al., 2005). Each of 
these TMAs contains relatively small patient numbers, varied and limited clinical patient data, 
and are primarily derived from pre-treatment excisional biopsies.  These small sample/patient 
numbers have often dampened the opportunities to assess proteins of interest in osteosarcoma 
and have limited the opportunity to make important associations between expressed proteins and 
patient outcomes.  The lack of TMAs with relatively large sample sizes that contain well-
documented clinical data and are derived from wide variety of sample types poses a serious 
challenge to physicians and researchers attempting to improve their understanding of 
osteosarcoma biology. The described characteristics of our array begin to address this unmet 
need. Although reported recently, we provide herein a complete description of the patient 
population as well as the patient numbers and sample types (Abdeen et al., 2009).  
The majority of samples included in this TMA were taken from patients who had 
received neoadjuvant chemotherapy but still had a large percentage of viable neoplastic cells at 
the primary tumor site. This patient population could a potential bias in the TMA design toward 
patients with a poor response to chemotherapy.  However, the 5-year overall survival rates for 
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patients included in our TMA with localized osteosarcoma (approximately 75%) is consistent 
with survival rates reported in the literature (Gurney, 1999; Meyers, 2008).  
As an example of our TMA’s utility we evaluated the expression of eIF4E in 
osteosarcoma tissues formatted on this array and assessed correlations between eIF4E 
expression, sample type, and overall survival. Our findings demonstrated that relatively uniform 
expression of eIF4E in both primary tumors and metastatic lesions of these osteosarcoma 
patients (Fig. 3.2A) and that eIF4E expression intensity was not an independent predictor of 
overall survival (Fig. 3.3B).  It is reasonable that the uniform expression of eIF4E in 
osteosarcoma tissues precluded its association with outcome. 
There has been a wealth of evidence in both experimental cancer models and in human 
cancer tissues implicating eIF4E with tumor development and progression. However, the 
majority of this work has been conducted in primary epithelial tumors.  There is very limited 
information about eIF4E expression and activity in cancers of mesenchymal origin, including 
osteosarcoma. Because eIF4E is overexpressed in many cancers and plays a role in oncogenic 
transformation and tumor progression, (De Benedetti and Graff, 2004; Mamane et al., 2004; 
Proud, 2007; Ruggero, 2004) many groups are working to develop strategies to effectively target 
eIF4E.   Novel agents in various stages of development include antisense oligonucleotides to 
eIF4E, RNAi or antisense RNAs that suppress eIF4E, a physical mimic of the natural ligand, 
suicide gene therapy, and peptide-based inhibition of eIF4E (Ko, 2009). The widespread 
expression of eIF4E in osteosarcoma may suggest the potential utility of these approaches in 
osteosarcoma. 
We report herein the development of a relatively large, outcome-linked TMA for use by 
the community.  Our TMA was built to complement other TMAs currently available and to 
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address the limitation of small sample size and to provide a wider variety of sample types that 
characterize the disease including pre-treatment excisional biopsies, post-treatment definitive 
resections, and lung metastases. We hope that our TMA will facilitate rapid evaluation of 
potential protein biomarkers and ultimately result in an improved understanding of osteosarcoma 
biology and therapy.   
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TABLE 3.2. Osteosarcoma tissue microarrays reported 
 
 
     TMAa  Samples Age Range           Sample   Grade  Huvos 
 (Patient #)b   (Mean)c            Type    Score 
 
      BXd DRe Mf 
 
Di Cristofano 58 (50)              Unknown 22 31 5 High-40              Unknown 
         Low-8 
 
Folio  46 (18)  6-29  11 0 7 High                   Unknown 
    1986-2001 (14.6) 
 
Kim  64 (64)  4-58 
  1995-2000 (19.4)  64 0 0 High              Unknown 
  Males-45 
Females-19 
 
Do  47 (47)         I-20 
  1983-2005 7-66  39 0 8 Unknown II-15 
Males-25 (25)       III-7 
Females-22        IV-1 
 
Salas  73 (73)  Unknown 73 0 0 Unknown           Unknown 
  1993-2007 
 
Somers  34 (18)         I-3 
  Males-12 7-17  13 11 10 High  II-5 
  Females-6 (12)       III-3 
           IV-0 
 
a TMA = Tissue microarray 
b Number of patients the samples are derived from 
c Age range and mean are measured in years 
dBX = pre-treatment biopsy 
e DR = post-treatment definitive resection 
f M = lung metastases 
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Chapter 4. Modeling Metastasis Biology and Therapy in Real Time in the 
Mouse Lung1 
 
ABSTRACT 
Pulmonary metastasis remains the leading cause of death for cancer patients.  Opportunities to 
improve treatment outcomes for patients require new methods to study and view the biology of 
metastatic progression.  Here, we describe an ex vivo Pulmonary Metastasis Assay (PuMA) in 
which metastatic progression of GFP-expressing cancer cells, from a single cell to the formation 
of multicellular colonies, in the mouse lung microenvironment was assessed in real time for up to 
21 days. The biological validity of this assay was confirmed by its prediction of the in vivo 
behavior of a variety of high- and low-metastatic human and mouse cancer cell lines and the 
discrimination of tumor microenvironments in the lung that were most permissive to metastasis.  
Using this approach, we provide what we believe to be new insights into the importance of tumor 
cell interactions with the stromal components of the lung microenvironment.  Finally, the 
translational utility of this assay was demonstrated through its use in the evaluation of novel 
therapeutics at discrete points in time during metastatic progression.  We believe that this assay 
system is uniquely capable of advancing our understanding of both metastasis biology and 
therapeutic strategies. 
 
                                                 
1 This chapter has been previously published. A Mendoza, SH Hong, T Osborne, M Khan, K Campbell, J Briggs, A 
Eleswarapu, L Buquo, L Ren, S Hewitt, EH Dakir, S Garfield, R Walker, G Merlino, J Green, K Hunter, L 
Wakefield, C Khanna Modeling metastasis biology and therapy in real time in the mouse lung. Journal of Clinical 
Investigation 2010:120(8): 2979-2988. Copyright © 2010, American Society for Clinical Investigation. Reprinted 
with permission. All rights reserved. 
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INTRODUCTION 
Pulmonary metastasis remains a leading cause of death for cancer patients (Eccles and Welch, 
2007; Krishnan et al., 2006).  Opportunities to improve outcomes for these patients require a 
greater understanding of the biology of metastasis. In addition, there is a need to evaluate novel 
therapeutics, in a timely manner, which specifically target metastases and metastatic progression. 
Simple in vitro assay systems are not sufficient to model the complex interaction between cancer 
cells and the surrounding microenvironment that are necessary for metastasis (Welch, 1997).  
Accordingly, in vivo models of metastasis, largely in mice, have been necessary. For the most 
part, these models provide endpoints of metastatic outcome (i.e. yes or no metastasis) and time to 
late-stage metastatic events.   
A temporal “black-box” exists during metastatic progression from single cells to grossly 
visible metastatic lesions at a secondary site.  Recent attempts to shed light on this process have 
included imaging strategies that allow some of the steps of metastatic progression to be followed 
in vivo (Henriquez et al., 2007).  However, these approaches often involve sophisticated and 
expensive imaging techniques which are time-consuming and do not easily allow serial 
assessment of early metastatic progression at secondary sites, particularly in the lung and at the 
single-cell level.  Challenges associated with studying metastasis have resulted in limited 
opportunities to include the assessment of novel treatment agents against metastatic endpoints 
(Khanna, 2008).  Therefore, an unmet need in the field of cancer research is a simple assay in 
which the process of metastatic progression at a secondary site can be reproduced and studied 
over time.  
An optimal assay would recapitulate the cellular and micro-environmental complexity of the 
metastatic site, within a native 3-dimensional architecture, while allowing an “open window” for 
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evaluation of metastatic progression.  With this a goal in mind, we have developed an ex vivo 
Pulmonary Metastasis Assay (PuMA) in which green fluorescent protein (GFP)-expressing 
cancer cells proliferate and progress in lung tissue.  This assay allows real-time assessment of 
progression from single metastatic cells to multi-cellular colonies in the lung.  This assay 
faithfully discriminates between high- and low-metastatic phenotypes of human and murine 
cancer cell lines and between lung (host) microenvironments most permissive to metastasis, 
demonstrating the relevance and value of the approach.  Finally, the assay can be easily scaled to 
allow for rapid screening of novel therapeutic agents at several dose and schedule combinations. 
Using this assay, we provide new data that support the importance of tumor cell interaction with 
stromal elements in the lung microenvironment as a critical determinant of the metastatic 
phenotype of cancer. The description and validation of this assay immediately provides 
researchers an opportunity to explore mechanisms for cancer progression at secondary sites and 
to optimally develop novel treatment approaches specific to cancer metastasis. 
 
MATERIALS AND METHODS 
Cell lines  
Murine osteosarcoma K7M2 and K7M2/Ezrin antisense 1.46 (Khanna et al., 2001), murine 
breast cancer 4T07 and 67NR (Aslakson and Miller, 1992), Met1, and DB7 (Borowsky et al., 
2005), human osteosarcoma HOS and HOS-MNNG (Rhim et al., 1977), human breast cancer 
MCF7/GFP and MDA231/GFP (Barkan et al., 2008), and murine Ink4a/Arf (N-Ras transformed 
Ink4a/Arf-null, p53-knockdown) and N-Ras transformed Ink4a-null melanoma cells (Ha et al., 
2007) were cultured in complete DMEM media (Invitrogen). GFP was stably expressed in all 
cells using pSICO-eGFP or p960-X1-685-eGFP lentiviral infection.  
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Lung organ culture medium  
Serum-free conditions used for lung culture were first described by Siminski et al. in 1992 and 
were modified as follows.  Culture-medium 1, 2X solution of M-199 (Invitrogen) was 
supplemented with crystalline bovine insulin 2.0 µg/ml, hydrocortisone 0.2 µg/ml (Sigma-
Aldrich), retinyl acetate 0.2 µg/ml (Sigma-Aldrich), penicillin 200 U/ml and streptomycin 200 
µg/ml (Invitrogen), and 7.5% sodium bicarbonate (Invitrogen).  Culture-medium 2 was used for 
media changes during the lung organ culture period; 1X solution of M-199 was supplemented 
with crystalline bovine insulin 1.0 µg/ml, hydrocortisone 0.1 µg/ml, retinyl acetate 0.1 µg/ml, 
penicillin 100 U/ml and streptomycin 100 µg/ml, and 7.5% sodium bicarbonate. Then a 1.2% 
low-melting agarose solution (FMC BioProducts) was prepared with sterile distilled water. The 
agarose solution was melted via microwave and kept at 40 °C before use in lung culture. The 
agarose solution was mixed with Culture-medium 1 (37 °C) at a 1:1 concentration. 
 
In vivo and ex vivo lung organ culture studies 
Animal care and use was in accordance with the guidelines of the NIH Animal Care and Use 
Committee. The overall technique of isolated lung organ culture is shown in Figure 1. Healthy 
GFP-positive tumor cells (2 x 105) were delivered by tail vein injection to either female BALB/c 
(Taconic), SCID/Beige (Charles Rivers), FVB/N (Jackson Laboratory) AKR/J- FVB/NJ F1, or 
DBA/2J - FVB/NJ F1 mice.  Within 15 min of tumor injection, the mice were euthanized by CO2 
inhalation. Using sterile surgical conditions in a laminar-flow hood, the mice were placed in 
dorsal recumbency. The sternum was removed to expose the lung. The trachea was then 
cannulated with a 20-gauge intravenous catheter (Terumo) and attached to a gravity perfusion 
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apparatus under constant 20 cm H2O hydrostatic pressure or by syringe infusion of 1.2 ml of 
well-mixed culture-medium 1/agarose solution (40 °C). The trachea, lungs and heart were then 
carefully removed and immediately placed in a cold solution of PBS containing penicillin (100 
U/ml) and streptomycin (100 µg/ml) at 4 °C for 20 min to solidify the agarose/medium solution. 
Complete transverse sections (1-2 mm in thickness) were made from each lobe using a #21 
scalpel blade, yielding 16-20 lung sections. Then 4 to 5 lung sections were placed on a single 1.5 
x 0.7 cm sterile Gelfoam (Pfizer-Pharmacia & Upjohn Co.) section that had been pre-incubated 
for 2 h in 6 cm tissue culture dish with Culture-medium 2.  Lung sections were incubated at 37 
°C in humidified conditions of 5% CO2.  Fresh Culture-medium 2 was replaced and lung tissue 
sections were turned over with a sterile iris thumb forceps every other day. Drug treatments were 
added to the culture media at either day 0 (early treatment) or day 21 (late treatment) of the 
culture period.  
 
Image analysis and quantification  
A LEICA-DM IRB fluorescent inverted microscope (Leica) and Retiga-EXi Fast 1394 Mono 
Cooled CCD camera (Qimaging) were used to capture images of GFP-positive tumor cells 
within the PuMA at 100 X magnification.  Fluorescent events within the PuMA were acquired 
using OpenLab software (Improvision). Metastatic burden was quantified by measuring the 
fluorescent area of metastatic cells in each lung section at each time point and was expressed as 
either mean fluorescent area (mean fluorescent area of each lung section over 4 lung sections) or 
total fluorescent area (sum of fluorescent area in 4 lung sections).  Fluorescent area (mean or 
total) was normalized to 100 pixels for day 0 to allow quantitative evaluation of metastatic 
progression over time. 
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Histology/immunohistochemistry  
Formalin-fixed, paraffin-embedded mouse lung culture tissue sections were prepared at 5 µm on 
a transverse plane.  Sections were examined using H&E and special filament stains (cytokeratin 
and vimentin; data not shown).  Movat’s pentachrome histochemical staining technique was used 
to determine the presence of specific connective tissue, muscular, and cellular components. 
Expected Movat staining results: nuclei (dark purple to black), elastic fibers (black), muscle and 
red blood cells (red), collagen and reticular fiber (yellow), mucosubstance (blue to blue-green) 
and cytoplasm (pink to brownish-red) (Movat, 1955). Ki-67 staining was performed using the 
LSAB®+ System-HRP kit (Dako North America, Inc) as previously described (Hsu et al., 1981). 
Purified mouse monoclonal antibody for Ki-67 (1:25, BD Biosciences) was diluted in blocking 
buffer and incubated overnight at 4 ºC.  Negative-control incubation was performed by 
substituting non-immune serum for the primary antibody.  Following primary antibody 
incubation, slides were washed with PBS three times and incubated in biotinylated goat anti-
mouse IgG secondary antibody (Dako North America, Inc) in 1:500 Dako antibody diluent for 1 
h at room temperature.  Streptavidin peroxidase was applied to slides for 30 min at room 
temperature.  Color development was achieved by applying a 3-3’ diaminobenzidine chromagen 
solution.  Tissues were counterstained with hematoxylin (Sigma-Aldrich, Inc), dehydrated in a 
series of graded alcohols ending in xylene, mounted with coverslips and examined by light 
microscopy. Tissues from murine pulmonary metastatic osteosarcoma lesions were used as 
positive controls for Ki-67. 
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Transmission electron microscopy (TEM)   
Mouse lung tissues were fixed in 4% formaldehyde and 2% glutaraldehyde (Tousimis) in 0.1 M 
cacodylate buffer (Electron Microscope Science) and processed for TEM procedures.  Briefly, 
the tissues were washed in cacodylate buffer, post-fixed in osmium tetroxide (1% in same buffer) 
(Electron Microscope Science), and en bloc stained in uranyl acetate (0.5% in 0.1M acetate 
buffer pH4.2) (Electron Microscope Science).  The tissues were dehydrated in a series of ethanol 
(e.g., 35%, 50%, 75%, 95% and 100%) followed by propylene oxide and incubated in an equal 
volume of propylene oxide and epoxy resin overnight.  The tissues were embedded in a resin and 
cured in a 55 °C oven for 48 h.  The thin-sectioned (75 nm) samples were mounted on a copper-
meshed grid, stained in uranyl acetate (Electron Microscope Science) and lead citrate (Leica) 
prior to the EM examination.  The digital images were taken using a H7600 microscope (Hitachi) 
equipped with an AMT camera (Advanced Microscopy Techniques Co.). 
 
Comparison of metastatic progression in PuMA versus in vivo experimental metastasis 
Twelve SCID mice received tail vein injection of the metastatic HOS-MNNG human 
osteosarcoma cell lines on day 0 of the experiment.  Lungs from three of the mice were 
processed within the PuMA with image capture on day 0, 7, 14, and 21. Nine mice were 
followed in vivo.  Three mice from this in vivo group were euthanized and imaged on days 7, 14, 
and 21 in an identical manner to the PuMA.  Image analysis and quantification of metastastic 
progression was identical for both groups.  
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Statistical analyses  
The statistical significance between high-metastatic and low-metastatic tumor burden was 
determined by unpaired t test with Welch’s correction using Prism (version 4; GraphPad 
software). P < 0.05 was considered statistically significant. 
 
RESULTS 
Pulmonary Metastasis Assay (PuMA)   
We report herein on a metastasis assay that allows real-time assessment of metastatic 
progression in ex vivo cultures of lung tissue (Fig. 4.1). Using the reported assay conditions, the 
lung architecture was maintained for over 21 days (Fig. 4.2) and provided a 3-dimensional 
collagen network with associated lung epithelial cells, inflammatory cells, and other stromal 
elements with which fluorescent metastatic cells interacted and then progressed to form 
metastatic colonies (Fig. 4.3 and 4.4). Routine histological examination (Fig. 4.2A), Movat 
pentachrome histochemical stains for connective tissue components (Fig. 4.2B), and electron 
microscopy (Fig. 4.2C) confirmed the maintenance of physiologically relevant collagen lung 
architecture over a 21-day period of ex vivo PuMA (Fig. 4.2). Confocal second harmonic 
generation (SHG) imaging of lung tissues confirmed the maintenance of a 3-dimensional 
collagen lattice in lung tissues (data not shown).  Cell types present in the PuMA at early time 
points following lung culture included migratory cells, type I and type II pneumocytes, alveolar 
macrophages, vascular endothelial cells and red blood cells, airway associated epithelial cells, 
and stromal cells. The number and viability of some cellular populations declined through 21 
days of culture (Fig. 4.2). 
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Figure 4.1. Schematic summarizing the Pulmonary Metastasis Assay (PuMA) 
experimental approach. (A) GFP-positive tumor cells (2 x 105) were delivered to mice by 
tail vein injection. (B) Following euthanasia, the trachea was cannulated with a 20-gauge 
intravenous catheter and attached to a gravity perfusion apparatus. The lungs were infused 
with agarose solution in the vertical position under a constant 20 cm H2O hydrostatic 
pressure. (C) The lungs were allowed to cool at 4 °C for 20 min to solidify the agarose 
medium solution. Complete transverse serial sections (1-2 mm in thickness) were gently 
sliced from each lobe with a scalpel yielding 16-20 lung slices per lung. (D) 4 to 5 lung 
sections were placed on the sterile Gelfoam sections bathing in culture media. (E) Images 
were acquired and the area of GFP-positive cells in the each lung was quantified. Scale 
bar: 200 µm. 
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 Figure 4.2 Demonstration of a viable and structurally intact pulmonary architecture in PuMA. (A) PuMA 
yields an intact lung microarchitecture. Day 0- Bronchioles (B) were lined by epithelia that contact the 
basement membrane. Alveoli (A) were uniformly expanded throughout the lung and the alveolar walls (AW 
with arrow heads) were normal thickness. The alveolar walls contained small numbers of migratory 
inflammatory cells, pneumocytes (type I and II), and endothelial cells. Blood vessels and alveolar capillaries 
were expanded by red blood cells (RBCs). Day 7- Alveoli remained expanded. There were decreased 
numbers of migratory cells, pneumocytes, and endothelial cells in the alveolar walls and many of those that 
remained contained pyknotic nuclei. Days 14 and 21- Alveoli, airways, and large vessels (PA – pulmonary 
arteries; PV – pulmonary veins) remained expanded. Alveolar capillaries and RBCs were no longer 
discernable, and the alveolar walls contained fewer migratory cells and pneumocytes (loss of cellularity). 
Overall, lung microarchitecture was remarkably unchanged. (B) Movat stain was used to examine the 
connective tissue components of the lung culture. Black elastin fibers were present in large vessels, the 
basement membrane supporting the airway epithelia, and within the alveolar interstitium.  Black nuclei were 
scattered throughout the alveolar interstitium.  Red muscle surrounded arteries and larger airways (B) and 
yellow collagen fibers were in the surrounding vascular submucosa and alveolar interstitium.  Each of these 
components was identified at each time point. (C) Transmission Electron Microscopy. Stromal elements 
composed of collagen microfibers (C) were evident from day 0 through day 21. Scale bar: 100 µm (A and 
B); 1 µm (C). 
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Figure 4.3. Immunohistochemical staining of highly metastatic osteosarcoma cells for Ki-67 in 
PuMA. (A) Positive and negative control, (B) Ki-67 immunohistochemical staining, and (C) 
H&E staining of PuMA sections confirmed proliferative competency of metastatic osteosarcoma 
cells, most notably at days 14 and 21. Tissue from a primary osteosarcoma lesion was used as a 
positive control for Ki-67. A, Alveoli. Scale bar: 100 µm. 
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Serial assessment of metastatic progression from single cells in PuMA   
Fluorescent metastatic cells were identified microscopically and images were captured to 
quantify single metastatic cells and metastatic clusters using epi-fluorescence or confocal 
microscopy (Fig. 4.1 and 4.4). To validate the utility of the PuMA for the study of metastatic 
progression, we first compared previously described highly metastatic versus non-metastatic 
clonally related human (Rhim et al., 1977) and murine (Khanna et al., 2000) osteosarcoma cell 
lines.  Osteosarcoma is a highly metastatic pediatric cancer with a high proclivity for lung 
metastasis.  These cell lines have similar in vitro growth properties, equally form primary tumors 
in mice, yet show distinctive in vivo phenotypes in both experimental (i.e. tail vein injection) and 
spontaneous (i.e. orthotopic injection) metastasis models in mice.  As shown in Figure 4.4, the 
number of metastatic cells that arrive in the lung with the high and low metastatic cell lines is 
similar at early time points.  Indeed, differences in the metastatic phenotype only became evident 
by day 7 in PuMA with the highly metastatic cell lines forming small multicellular colonies 
(approximately 10-15 cells), whereas the clonally related, non-metastatic cell lines formed few 
multicellular clusters and then showed progressive decline in the number of single metastatic 
cells.  The localization of single tumor cells was visualized by merging fluorescent images of 
metastatic cells with confocal SHG reconstruction of the collagen matrix of the lung. By day 14, 
large metastatic colonies were evident in the lung tissue containing highly metastatic 
osteosarcoma cell lines whereas very few cells could be identified in lung tissue containing low 
metastatic cell lines (Fig. 4.4, A-D). Interestingly, similar to our observations from in vivo 
studies of metastasis in mice, most metastatic colonies were observed at the periphery of the lung 
sections.   
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Figure 4.4. The PuMA distinguishes the phenotype of metastatic from non-metastatic cell lines.  
(A and B) Serial imaging of fluorescently labeled high and low metastatic human and murine 
osteosarcoma cells. Similar numbers of cells were seen at day 0; however, a difference between 
high and low metastatic cell lines was seen at day 7. Representative fields from lung are shown. 
Scale bar: 200 µm. (C and D) Quantification of metastatic burden (mean normalized fluorescent 
area) from A and B reveals a significantly lower sum of GFP positive cell area in the lung 
section following injection of low metastatic human and murine osteosarcoma cells.  Similar 
results were generated using high and low metastatic pairs of human and murine breast cancer 
cells and murine melanoma cells (See Table 4.1).  Quantification of metastatic progression in 
PuMA was validated using both mean fluorescent area and enumeration of surface metastatic 
colony count. 
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In order to demonstrate that the metastatic tumor cells were actively proliferating in the lung 
cultures, Ki-67 immunohistochemical staining was conducted during the culture period (Fig. 
4.3). Indeed, positive Ki-67 staining was observed in metastatic tumor cells in the PuMA.  This 
included single metastatic cells early after their arrival in the lung and in larger metastatic 
colonies at later time points.  In addition, Ki-67 immunoreactivity was observed in the alveolar 
interstitium demonstrating the viability of alveolar interstitial cells in this assay.  As further 
validation that metastatic tumor cell numbers increased over time in PuMA, quantitative real-
time PCR for the eGFP transgene was performed on genomic DNA isolated from lung slices 
containing metastatic tumor cells at multiple time points. As expected, the eGFP DNA copy 
number increased over time, indicative of increased tumor cell number and consistent with 
fluorescent evaluation showing metastatic progression.   
To further validate the utility of the assay in the study of metastasis biology we examined a 
larger series of clonally related cancer cell lines with known differences in metastatic phenotype 
(Summary in Table 1) (Aslakson and Miller, 1992; Barkan et al., 2008; Borowsky et al., 2005; 
Ha et al., 2007; Khanna et al., 2001; Lifsted et al., 1998; Rhim et al., 1977). The kinetics of 
metastatic progression in the PuMA were distinct for each cancer cell line assessed (Fig. 4.4). 
Nonetheless, in each case, the clonally related variants with greater propensity for metastasis in 
vivo were also associated with greater metastatic phenotype in the PuMA.  It is important to note 
that metastatic phenotypes of these cell line pairs are indistinguishable in conventional 2-
dimensional culture conditions (Table 1). 
A direct comparison of the PuMA with in vivo experimental metastasis using identical cell 
lines and assessment points suggested that the kinetics of metastatic progression in the PuMA 
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and in vivo are similar (Fig. 4.5). The primary difference between PuMA and in vivo 
experimental metastasis was the duration of the initial period of metastatic inefficiency, during 
which the number of single metastatic cells detected in the lung was reduced.  In the in vivo 
experimental metastasis setting, this period of inefficiency for osteosarcoma cells was most 
notable at day 7.   In the PuMA, the metastatic inefficiency for these osteosarcoma cells was 
most notable at day 4 and had begun to recover at day 7. Similar and more extreme patterns of 
metastatic inefficiency were seen in both PuMA and the in vivo setting using non-metastatic 
cells (data not shown). Beyond the calibration between PuMA and the in vivo settings, these data 
suggest that a primary determinant of early metastatic inefficiency is survival of metastatic cells 
in the lung and is not merely a function of blood flow “washing away” metastatic cells from the 
lung. 
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Table 4.1. Descriptive summary of concordance between PuMA and in vivo studies of 
metastasis biology 
 
Metastasis biology  PuMA metastatic phenotype  In vivo metastatic phenotype  In vitro metastatic phenotype 
   is discernibleA   is discernibleB   is discernibleC 
 
Human osteosarcoma   Yes          Yes              No 
Murine osteosarcoma  Yes          Yes              No 
Human breast cancer   Yes          Yes              No 
Murine breast cancer   Yes          Yes              No 
Murine melanoma  Yes          Yes              No 
Murine host microenvironments Yes          Yes              No 
 
A Discernible: can a blinded investigator distinguish metastatic and non-metastatic cells in the PuMA assay? Refer to Figure 4.4 
for actual experimental data. 
B  Discernable: can a blinded investigator distinguish metastatic and non-metastatic cells in the in vivo studies?  
C  Discernable: can a blinded investigator distinguish metastatic and non-metastatic cells in conventional in vitro tissue culture 
conditions? 
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Figure 4.5. Similarities in metastatic progression in vivo compared to PuMA.  A direct 
comparison of the metastatic phenotype of human osteosarcoma cell lines in vivo 
(experimental metastasis) and in the PuMA was conducted.  (A and B) Serial imaging of 
fluorescently labeled high and low metastatic human osteosarcoma cells was conducted in 
the PUMA.  At the identical time points as in the PuMA, lungs from mice that had received 
tail vein injection of tumor cells were collected and imaged.  Patterns of pulmonary 
metastatic progression were similar in both in vivo and PuMA.  Representative fields from 
lung are shown. Scale bar: 200 µm. (C and D) Quantification of metastatic burden (mean 
normalized fluorescent area) from A and B.  Identical results demonstrating the similarities 
in pulmonary metastatic progression for murine osteosarcoma cells were seen in vivo and 
in the PuMA. 
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Since the PuMA includes cellular and stromal elements of the host, we next asked if this novel 
system might also allow microenvironmental (i.e. host) influences on metastatic progression to 
be assessed. AKR/J and DBA/2J represent murine genetic backgrounds in which primary tumor 
initiation and growth kinetics are identical, but where there is a 20-fold difference in metastatic 
propensity (Lifsted et al., 1998).  As predicted by in vivo studies, a more aggressive pattern of 
metastatic progression was seen for mammary cancer cells in the AKR/J as compared to DBA/2J 
mouse lung sections (Fig. 4.6 and Table 1). These results support the hypothesis that metastasis-
associated differences in genetic background that have been previously reported are indeed the 
result of differences in the local tumor microenvironment (i.e. lung microenvironment).  
Furthermore, given the absence of a systemic immune component in the PuMA, these data 
suggest the importance of stromal elements of the extracellular matrix in the lung as primary 
determinants of the role of the tumor microenvironment on metastatic progression.  These data 
further underscore the opportunity to evaluate both tumor and microenvironmental influences 
linked to metastatic progression within the PuMA.   
 
Screening of therapeutic agents with potential activity against metastatic progression and 
metastases   
Finally, we sought to determine if the PuMA could be used to identify anti-metastatic agents.  
The ability of therapeutic agents to diffuse through the culture media into the gelfoam material 
and into the lung section tissues was tested within the PuMA using tumor cells that expressed 
GFP under the control of a doxycycline-sensitive promoter.  Within 24 h of addition of 
doxycycline to the culture media of the PuMA, we observed expression of GFP in tumor cells.    
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We then compared the activity of therapeutic agents in PuMA in relation to their activity in 
conventional transplantable murine models (summarized in Table 4.2). Evaluated therapeutic 
agents included conventional cytotoxic chemotherapy (treosulfan) and the prototypic mTOR 
pathway inhibitor (rapamycin). Consistent with in vivo results (Wan et al., 2005), rapamycin 
exposures to the PuMA significantly inhibited metastatic progression at 1 µM. The anticancer 
activity of Treosulfan, a non-targeted cytotoxic chemotherapy, has been shown in vitro and in 
vivo against a variety of pediatric sarcoma cell lines (Werner et al., 2008).  Significant activity of 
these agents was confirmed in the PuMA following their addition early or late during the course 
of metastatic progression. The throughput and flexibility of the PuMA allowed several doses of 
each agent to be assessed against metastatic progression in a short period of time. The real-time 
observation provided by the assay allowed the assessment of each agent against either the entire 
metastatic progression, from single metastatic cells to metastatic clusters, or at discrete points in 
the course of metastatic progression in the lung.  
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Table 4.2. Descriptive summary of the use of PuMA in translational evaluation of novel anticancer 
agents with activity against metastasis  
 
Metastasis therapy Anticancer activity Antimetastatic activity Anticancer activity 
           in PuMA               in vivo             in vitro  
     
Rapamycin (14)  Yes    Yes         Yes  
      
Treosulfan (15)  Yes    Yes         Yes  
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Figure 4.6. The PuMA can distinguish host microenvironments that are 
permissive.  (A) Serial imaging of fluorescently labeled low metastatic murine 
breast cells (DB7) in high (AKR/J) and low (DBA/2J) metastatic murine host 
microenvironments. Similar numbers of metastatic cells are seen at day 0 in both 
lung environments; however, a difference in metastatic progression between high 
and low metastatic microenvironments can be seen at day 7. Representative fields 
from lung are shown. Scale bar: 200 µm. (B) Reduced metastatic burden 
(quantified by total normalized fluorescent lung area) was seen in the low 
metastatic phenotype of DAB/2J lung sections. Total metastatic burden in each 
lung section was normalized to day 0 and followed over time.  
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DISCUSSION 
 The PuMA is an ex vivo, closed system and sterile assay that allows assessment of 
metastatic progression from single cells to metastatic clusters up to and beyond a 21-day 
observation period.  During this time, metastatic tumor cells interact with the 3-dimensional 
collagen network within the lung (the primary constituent of the lung architecture) and 
associated lung epithelial cells, inflammatory cells, and other stromal elements. Fluorescent 
metastatic cells and metastatic lesions were quantified for number, size and localization during 
this period. The relevance of the PuMA was confirmed by its ability to accurately define the 
metastatic phenotype of tumor cell lines with previously established high versus low metastatic 
behaviors in vivo. These predictions are noteworthy since the metastatic phenotype of these cells 
is not distinguished by growth in conventional in vitro culture conditions. Given the recognized 
importance of the tumor-microenvironment interactions for metastatic progression, it was 
particularly revealing to see that the PuMA was used effectively to compare the influences of 
distinct host microenvironments on the progression of identical tumor cells. These new data 
suggest the importance of the local microenvironment rather than systemic response of the host 
on the metastatic phenotype.  Finally, the opportunity to use this PuMA approach as a 
translational drug development tool was then supported by the evaluation of both cytotoxic and 
molecularly targeted therapeutics against metastatic progression.  Importantly, the flexibility of 
the assay allowed rapid assessment of multiple drug doses, exposure times and schedules.  The 
PuMA fills an unmet need in the study of metastasis biology and therapy by allowing the real-
time assessment of metastatic progression in a relevant tumor microenvironment.  
A critical component of the assay conditions reported herein was the insufflation of 0.6% 
agarose to the lung (Cifone and Fidler, 1980).  Without agarose insufflation the lung structure 
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was completely lost within 24 h. The influence of agarose density on metastatic tumor cell 
growth has been previously assessed (Cifone and Fidler, 1980). Conventional microscopy, 
immunohistochemistry, electron microscopy and second harmonic generation microscopy 
demonstrated the collagenous nature of the lung architecture.   Based on confocal fluorescent 
microscopy and second harmonic generation imaging  (which images the collagen matrix of the 
lung), we hypothesize that the 3-dimensional collagen lattice that is retained in the PuMA is a 
critical scaffold on which tumor cells interact with other cells of the lung microenvironment. We 
and others have hypothesized that the survival of tumor cells at distant secondary sites is 
stressful and that this stress is a primary contribution to the inefficiency of the metastatic process 
(Chambers et al., 1995; Khanna et al., 2001).  Based on the results of the PuMA it is reasonable 
to argue that metastatic cells have an enhanced capability to engage the local lung 
microenvironment and manage growth on the scaffolding of the lung collagen architecture than 
non-metastatic cells.  Indeed, survival in this 3-dimensional context may be the measurement of 
metastatic competency assessed in this assay. Our studies of differences in metastatic 
progression in the PuMA that result only from changes in the strain of mice used, now provide 
additional information on the importance of the interaction between tumor and tumor-
microenvironment as a critical determinant of (strain/host-dependent) metastatic success.  These 
data in the PuMA provide a unique perspective on the importance of the non-cellular stromal 
elements of the lung microenvironment in the progression of lung metastasis. It is recognized 
that different mouse strains express different ECM components.  These include stromal elements 
observed within the microarray prognosis signatures for metastatic cancers. Based on the PuMA 
data, we suggest that tumor cells are responding differently to the subtle variations of ECM 
composition that either induce or suppress growth in the secondary site. These data are 
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concordant with recent reports on the role of lung collagen in regulating the dormancy phenotype 
of some metastatic cancers (Barkan et al., 2008). 
The PuMA provides an opportunity to visualize and monitor the progression of metastasis in 
the lung in ways not previously possible. For example, using existing in vivo mouse models we 
are unable to easily assess the full range of steps and cellular processes involved in metastatic 
progression in the lung despite the application of sophisticated imaging approaches (Cameron et 
al., 2000).  Furthermore, the PuMA complements recent assay approaches used to monitor 
metastatic progression, such as intravital videomicroscopy (IVVM) (Al-Mehdi et al., 2000; 
MacDonald and Chambers, 2006).  Unlike PuMA, IVVM allows the study of metastasis in the 
context of living tissue with blood flow.  IVVM is constrained by a relatively short window of 
observation, most commonly restricted to hours after cellular arrival at secondary sites.  Other 
effective approaches to image metastatic progression in the lung can be confounded by the 
impact of surgery needed to expose the lung and the influences of respiring or ventilated lung on 
image quality. In addition, several simple 3-dimensional in vitro culture systems have been used 
to study the metastatic phenotype of cells.  However, these approaches fail to model the 
complexity of tumor cell-tumor microenvironment interactions necessary for metastasis 
(Themistocleous et al., 2004). Our current description of the PuMA addresses many of the 
shortcomings of currently available methods to study metastasis biology. Indeed a direct 
comparison of PuMA with in vivo experimental metastasis demonstrated the similarity in 
metastatic progression seen in both ex vivo and in vivo conditions. It is reasonable, and our 
expectation, that the PuMA will provide opportunities for several future investigations of 
metastasis biology including determinants of the metastatic tumor cell, the tumor 
microenvironment and their interaction. 
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Finally, the PuMA provides a novel approach to specifically evaluate the efficacy of anti-
cancer agents in the context of metastatic progression at a secondary site. Despite the fact that 
the most common cause of death in cancer patients is metastasis, current preclinical drug 
development models do not prioritize metastasis endpoints in their evaluation of new drug 
candidates.  This is due, in part, to the inability to model metastatic progression or metastatic 
lesions outside the mouse. It is also due to the fact that in vitro assays of specific metastatic 
processes (i.e. motility or invasion) are, alone, not always informative.  Although not a high-
throughput option, the PuMA provides an efficient assessment of several drug/dose/schedule 
combinations over time.  Furthermore, the PuMA allows the evaluation of a new drug candidate 
against either single metastatic cells or advanced metastatic lesions.  In this way, the PuMA may 
be useful in identifying or prioritizing novel cancer therapy agents for use against metastatic 
progression or metastatic lesions and should therefore accelerate the development of new 
treatments for patients with metastasis.  
Although not investigated herein, the PuMA will provide an opportunity to study later points 
in metastatic progression, i.e., from metastatic colony formation to development of gross 
metastatic lesions.  This may be accomplished by delaying the initiation of the PuMA for days or 
weeks after the injection of tumor cells into mice. By delaying the initiation of PuMA, the same 
experimental methodology reported here may also be used following spontaneous metastasis of 
tumor cells from either orthotopic or heterotopic sites. 
The PuMA allows real-time assessment of metastatic progression from single cells in the lung 
to multi-cellular colonies. This novel experimental approach fills an important gap in the field of 
metastasis research by allowing real-time assessment of metastatic progression from single cells 
in the lung to multi-cellular colonies and beyond.  The PuMA also provides an informative 
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unique opportunity to study the local host (i.e. stromal) determinants of metastatic progression in 
cancer. The description and validation of this assay provides investigators with an immediate 
opportunity to explore mechanisms for cancer progression at secondary sites and to optimally 
develop novel treatment approaches for cancer metastasis.   
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Chapter 5. Evaluation of Eukaryotic Initiation Factor 4E (eIF4E) in 
Metastatic Osteosarcoma 
 
ABSTRACT  
 
The most significant problem for cancer patients is the dissemination of cancer cells and the 
formation of metastatic disease.  Emblematic of the problem is the clinical progression seen in 
most patients with osteosarcoma, where metastasis to the lung is the most common cause of 
death. Cancer cells are believed to efficiently regulate protein translation at specific times and 
locations in a cell in response to changes in their environment. Within the process of protein 
translation the abundance and activation of the mRNA cap-binding phosphoprotein, eukaryotic 
initiation factor 4E (eIF4E) is considered to be both rate- and process-limiting.  Based on this 
observation we asked if eIF4E was necessary or sufficient for metastasis in preclinical models of 
osteosarcoma.  We overexpressed and knocked down eIF4E expression in murine and human 
osteosarcoma cell lines and then evaluated the consequences at various steps within the 
metastatic cascade in vitro and in vivo. Here, we report that suppression of eIF4E significantly 
delayed migration (P < 0.001) and reduced the number and size of colonies that formed in soft 
agar (P < 0.001). Additionally, suppression of eIF4E inhibited spontaneous pulmonary 
metastases. eIF4E overexpression did not change the phenotype of previously non-metastatic 
cells.   Taken together, our data suggest eIF4E may be a necessary, but not sufficient, 
requirement for metastasis in osteosarcoma.  
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INTRODUCTION 
Osteosarcoma is the most common malignant tumor of bone. The primary cause of death 
for these patients is the development of metastasis. Despite intensification of chemotherapy and 
multimodality treatments, 30% of patients with localized disease will have recurrence within 5 
years, primarily to the lung.  Furthermore, less than 20% of patients that present with metastatic 
disease will be cured.  Long-term outcomes for osteosarcoma patients have not improved in over 
20 years (Meyers, 2009). In order for patient outcomes to improve, we must improve our 
understanding of osteosarcoma metastasis.  
The metastatic cascade is a complex, multistage process. Within this process, each step is 
subject to a wide variety of influences. The progression from a normal cell to a malignant tumor 
involves numerous genetic alterations. Metastasis promoters and metastasis suppressors are two 
broad classes of genes that contribute to the metastatic phenotype. These genes are thought to 
function in normal development and physiology such as cell migration, tissue invasion, and 
angiogenesis, but are co-opted by the cancer cell in the metastatic cascade (Khanna and Helman, 
2006). Ezrin, the cytoskeleton linker protein that connects the plasma membrane to the actin 
cytoskeleton has been identified as a metastasis-associated gene in murine, canine, and human 
osteosarcoma (Khanna et al., 2004). We have hypothesized and demonstrated that ezrin provides 
a survival advantage to metastatic cells by enabling the efficient translation of critically required 
proteins (personal communication, Joe Briggs). The efficiency of expression of proteins involved 
in cell growth regulation, proliferation or cell death may be controlled at the translational level 
by changes in the activity of components of the protein synthesis machinery.  
There is now a growing body of evidence that suggests links between dysregulation of 
protein synthesis and malignant progression of cancer. To progress through the metastatic 
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cascade requires cooperative function of numerous proteins that facilitate invasion (e.g., matrix 
metalloprotease (MMPs)), survival (e.g., Bcl-2), and angiogenesis (e.g., vascular endothelial 
growth factor (VEGF)) (Graff and Zimmer 2003).  Although expression of these proteins may be 
regulated at many levels by various stimuli, translation of proteins is likely regulated primarily 
by eukaryotic initiation factor 4E (eIF4E). A model describing a hierarchy of weakly and 
strongly translated proteins in cells has emerged (Baserga, 1990; Graff and Zimmer, 2003). 
These proteins are differentially regulated by translation. The “strongly translated” proteins are a 
stable set of “less regulated” proteins with short, unstructured 5’ untranslated regions (UTRs) 
that are expressed at a basal rate with limited input from external stimuli. In contrast, “weakly 
translated” proteins typically have lengthy, G-C rich, highly structured 5’UTRs and are 
maintained as stable mRNA transcripts. These so-called weakly translated proteins are not 
translated unless the translational machinery is upregulated by stimuli such as growth factors or 
cellular stress (Bjornsti and Houghton, 2004; De Benedetti and Graff, 2004; Sonenberg and 
Dever, 2003). The model of weakly and strongly translated proteins suggests that under specific 
signals and requirements, specific proteins can be translated and delivered to specialized 
locations in the cell (Richter and Sonenberg, 2005). For example, when the cell is exposed to 
stress or growth factors, there is an increased concentration of eIF4E available to bind with the 
eIF4F complex creating the specifically enhanced translation initiation the weakly translated 
proteins require for efficient translation. The end result is disproportionately enhanced translation 
of weak proteins (De Benedetti and Graff, 2004). Cancer cells are believed to efficiently regulate 
protein translation at specific times and locations in a cell in response to changes in their 
environment.  
eIF4E is a 25 kDa cytosolic cap-binding protein that is involved in the mRNA-ribosome 
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binding step of eukaryotic protein synthesis. It exists as both a free form and as part of a 
multiprotein complex termed eIF4F. Other subunits of the eIF4F translation initiation complex 
include eIF4A, a 46-50 kDa ATP-dependent polypeptide that has RNA helicase activity and a 
185-220 kDa scaffolding polypeptide termed eIF4G that acts as a docking site for several 
proteins needed to bridge the ribosome and mRNA. eIF4G binds to both eIF4E and eIF4A 
(Gosselin et al.; Haghighat and Sonenberg, 1997) .  Since eIF4E is the least abundant component 
of the translation initiation machinery, its abundance and activation are considered both rate- and 
process-limiting within translation initiation (Fan et al., 2009; Pain, 1996). The function of 
eIF4E is to bind the 7-methyl guanosine (m7G) cap structure found on the 5’ end of an mRNA 
and bring it to the ribosome for protein synthesis.  The activity of eIF4E is modulated by 
phosphorylation, regulation of its transcription, and its interaction with eIF4E-binding proteins 
(4EBPs) (Raught and Gingras, 1999). In addition, eIF4E’s activity is affected by a wide range of 
extracellular stimuli including growth factors, hormones, availability of nutrients, cytokines and 
various cellular stresses (Pain, 1996).  
Increased levels or activity of eIF4E results in selectively enhanced translation of a subset 
of mRNAs that play a role in cell proliferation (cMYC, CDK2, cyclin D1), angiogenesis (VEGF, 
fibroblast growth factor 2 (FGF2)), evasion of apoptosis (Mcl-1, Bcl-2, survivin), and 
metabolism (MMP9, heparanase) (Hsieh and Ruggero, 2010; Konicek et al., 2008; Silvera et al., 
2010). Under physiologic conditions, these proteins are translationally repressed but are 
activated in cancer. Through this translational control of cancer-associated genes, eIF4E is 
believed to be an important modulator of cell growth and proliferation (Sonenburg and Gingras, 
1998) and is  overexpressed in a number of malignancies including lymphomas, cancers of the 
breast, lung, head and neck, bladder, prostate, colon and rectum (De Benedetti and Graff, 2004), 
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esophagus (Salehi, 2006), skin (Salehi, 2007),  and cervix (Matthews-Greer, 2005). While there 
has been a wealth of evidence in both experimental cancer models and in human cancer tissues 
implicating eIF4E with tumor development and progression, the majority of this work has been 
conducted in epithelial tumors and mouse fibroblast cells.  Accordingly, we first asked about the 
expression and distribution of expression intensities for eIF4E in human osteosarcoma.  Using 
immunohistochemical expression profiling of eIF4E in a human osteosarcoma TMA including 
pre-treatment excisional biopsies, post-treatment definitive resections, and lung metastases, our 
laboratory recently determined eIF4E to be similarly expressed in both primary tumors and 
metastatic lesions of these osteosarcoma patients (Chapter 3). In the current study we sought to 
define the biological role of eIF4E in the metastatic phenotype of osteosarcoma by stably 
overexpressing and knocking down eIF4E in poorly and highly metastatic mouse and human 
osteosarcoma cell lines respectively and evaluating various steps of the metastatic cascade in 
vitro and in vivo. We found that forced constitutive overexpression of eIF4E in both mouse 
(K12) and human (HOS) osteosarcoma cells was not sufficient to change the metastatic 
phenotype of poorly metastatic cells in vitro or in vivo whereas, suppression of eIF4E decreased 
cellular migration, anchorage-independent growth, and spontaneous metastasis in vivo of human 
osteosarcoma cells (HOS-MNNG)  
 
MATERIALS AND METHODS 
 
Osteosarcoma cell lines and media 
High- and low-metastatic clonally related murine (K7M2 and K12, respectively) (Khanna et al., 
2000) and human (HOS-MNNG and HOS, respectively) (American Type Culture Collection, 
Rockville, MD) osteosarcoma cells lines were maintained in vitro using Dulbecco’s Modified 
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Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA) culture media containing 10% fetal bovine 
serum, L-glutamine (2 mmol), penicillin (100 units/ml), and streptomycin (100 µg/ml) at 37 °C 
in a humidified 5% CO2 incubator. For all in vitro and in vivo assays, cells were harvested using 
trypsin/EDTA (Invitrogen) from cultures at 70-95% confluence. All cell lines used were from 
early passages. Serum-free medium (SFM) and medium containing 5% fetal bovine serum were 
also used in select in vitro experiments. All cells were verified as Mycoplasma-free. 
 
Overexpression lentiviral constructs and virus production 
Constitutive stable overexpression of eIF4E was achieved by infecting poorly metastatic human 
(HOS) and murine (K12) osteosarcoma cell lines with a lentiviral construct, pSICO-CMV-cMyc-
meIF4E (human; HOS-4E) or pSICO-Pol2-cMyc-meIF4E (murine; K12-4E) which contained 
full-length eIF4E sequences. Controls were HOS and K12 cells infected with the lentiviral 
pFUGW-CMV-IRES-eGFP (HOS-EV) or pFUGW-Pol2-IRES-eGFP (K12-EV) expression 
vectors lacking eIF4E cDNA sequences. These lentiviral plasmid DNAs were co-transfected 
with Invitrogen packaging plasmids into HEK293T cells to generate VSV-g pseudotyped 
lentivirus particles. These cells were refed with complete medium 24 hours post-transfection and 
the culture supernatant harvested 48 hours post-transfection. The supernatant was clarified by 
centrifugation and filtration. To perform lentiviral infections, 1 x 105 target cells were plated in a 
6-well plate to 70% confluence and incubated overnight at 37 °C in a 5% CO2 chamber. On the 
day of infection, the culture medium was replaced by the appropriately titered viral supernatant 
(1 ml/well) and incubated overnight at 37 °C in a 5% CO2 chamber; afterward the viral 
supernatant was replaced with fresh medium. Forty-eight hours later, infected cell populations 
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were selected in Geneticin (G418; 400 mg/L). After 10 days of selection, overexpression levels 
were determined by Western blot analysis. 
 
Lentiviral shRNAs and plasmids and virus production 
Long-term, stable gene silencing was achieved using transduction-ready MISSION™ Lentiviral 
Particles (SIGMA, St. Louis, MO) that targeted human eIF4E. The target set consisted of five 
different sequences that were assessed individually (A-E) and pooled (P). All lentiviral 
constructs were assembled in the pLKO.1puro vector (www.sigma-aldrich.com/missionsearch). 
MISSION Non-Target shRNA Control Transduction particles were used as a negative control 
(NC). This non-targeting shRNA is produced from a non-target control plasmid and does not 
target any mouse or human genes. To perform lentiviral infections, 1 x 105 highly metastatic 
human osteosarcoma cells (HOS-MNNG) were plated in a 6-well plate to 70% confluence and 
incubated overnight at 37 °C in a 5% CO2 chamber. On the day of infections, the culture medium 
was replaced by the appropriately titered viral supernatant A, B, C, D, E, P, or NC (150 µl/well) 
and incubated overnight at 37 °C in a 5% CO2 chamber; the viral supernatant was then replaced 
with fresh medium. Forty-eight hours later, infected cell populations were selected in puromycin 
(0.5 µg/ml). After 14 days of selection, shRNA knockdown was determined by Western blot 
analysis. Lentiviral particles A (HOS-MNNG-A) and D (HOS-MNNG-D) produced the greatest 
knockdown (Fig. 5.1D). 
 
Western blot analysis 
Cells were lysed in 1X SDS lysis buffer. Equal amounts of protein were resolved on 4-12% or 4-
20% SDS-PAGE gels, and separated proteins were transferred to nitrocellulose membranes. 
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Membranes were blocked with 5% milk in Tris-Buffered Saline Tween 20 (TBS-T) and then 
incubated with rabbit polyclonal anti-eIF4E primary antibody (Cell Signaling Technology, 
Danvers, MA) overnight at 4 °C.  This was followed by incubation with horseradish peroxidase-
conjugated anti-rabbit IgG antibodies and developed by SuperSignal West Pico detection 
(Thermo Scientific, Rockford, IL) and subsequent exposure to film.  
 
Cap-binding assay 
eIF4E-infected cells were plated at 2 x 106 in a 10-cm Petri dish and incubated at 37 °C in a 
humidified 5% CO2 incubator for 24 hours. Lysates were prepared using m7GTP lysis buffer 
(500 µl/10 cm dish). BCA Protein quantification Assays (Thermo Scientific Pierce, Rockford, 
IL) were performed to determine the soluble protein concentration of each cell line. Cap-binding 
reactions were performed at 4 °C with sepharose-CL-4B (GE Healthcare) in wash buffer 1 [20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, complete protease inhibitors, complete phosphatase 
inhibitors] for 1 hour. Binding reactions were performed at 4 °C using m7GTP-sepharose or 
sepharose-CL-4B (negative control) in wash buffer 1 for 2 hours. Sepharose beads were washed 
2 times with 1 ml of wash buffer 1 and one time with wash buffer 2 [20 mM Tris-HCl (pH 7.5), 
300 mM NaCl, 1 complete Mini, EDTA-free protease inhibitor cocktail tablet (Roche 
Diagnostics, Indianapolis, IN), 1 mL 100X Haltphosphatase inhibitor cocktail (Thermo 
Scientific, Rockford, IL)] then resuspended in 2X SDS buffer for SDS-PAGE. Antibodies to 
eIF4E (Cell Signaling Technology) and c-Myc tag (Sigma) were used for Western blotting.  
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Wound healing assay (2D motility) 
Cells were seeded onto 6-well tissue culture plates and incubated in complete DMEM at 37 °C in 
a humidified 5% CO2 incubator. Once cells reached 95% confluence, the cell monolayer was 
scratched with a pipette tip (either a P1000 or P200) to generate a wound. The remaining cells 
were removed by washing with PBS and fresh complete medium to remove cell debris and a 
permanent black marker was used to identify the region of the “scratch” where images would be 
captured. Phase contrast images were captured using a Leica DMIRB inverted microscope at 
time points 0, 6, 12, and 24 hours. The extent of wound healing was determined by the distance 
(motility distance) traversed by cells migrating into the “wounded” area. The migration of the 
cells at the wound front image was captured, and the motility distance was measured in three 
independent wound sites per group. All experiments were performed in duplicate and repeated a 
minimum of three times.   
 
Cell proliferation assay 
One hundred microliters of cell cultures were seeded (2500 cells/well) into 96-well plates and 
cultured at 37 °C in a humidified 5% CO2 incubator for 4 hours. Cell Counting Kit-8 (CCK-8; 
DOJINDO Molecular Technologies, Inc., Rockville, MD) was used to evaluate cell proliferation. 
The CCK-8 assay was performed daily over a 4-day time course. Once a day, 10 µl of CCK-8 
reagent was added to cell culture and incubated for 2-3 hours. The plates were then read on a 
microplate reader using the reference wavelength of 450 nm. Six duplicates were done to 
determine each data point. 
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Soft agar assay for colony formation 
Cell lines were plated at 250 or 2000 cells per well and mixed with a 0.3% agarose solution in 
DMEM containing 10% FBS and layered on top of a 0.6% agarose base layer in 24-well tissue 
culture plates. The plates were incubated at 37 °C in a humidified 5% CO2 incubator for 3-4 
weeks and colonies were counted once a week. The results were reported as the mean number of 
colonies observed in 6-8 wells. All experiments were done in triplicate with two independent 
experiments.  
 
Cell migration assay 
In vitro tumor cell migration was assessed using a 24-Multiwell Insert System (HTS FluoroBlok, 
BD Biosciences) containing an 8 µm pore size PET (polyethylene terephthalate) membrane. 
Briefly, 0.5 ml of tumor cells (5 x 104 cells/ml) resuspended in serum-free DMEM was added to 
the upper chamber (in quadruplicate). DMEM medium containing 10% FBS was added to the 
lower chamber. The cells were incubated for 18 hours at 37 °C in a humidified 5% CO2 
incubator. Migrated cells were then stained with 5 mM Calcein AM (Molecular Probe) in HBSS 
buffer for 1 hour at 37 °C. To quantify tumor cell migration, fluorescently labeled cells were 
detected at an excitation wavelength of 485 nm and emission wavelength of 530 nm using a 
Wallace Victor 3 microplate reader (Perkin-Elmer, Wellesley, MA). Migration experiments were 
repeated at least three times.  
 
Murine experimental metastasis assays 
All animal studies, including maintenance and determination of experimental endpoints were 
performed under approval of the National Cancer Institute, Animal Care and Use Committee. To 
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examine experimental lung metastasis, 1 x 106 cells/ 0.1 ml of HBSS were injected directly into 
the lateral tail vein of 6- to 8-week-old female SCID beige (HOS or HOS-MNNG) or BALB/c 
(K12) mice respectively. Metastatic disease progression was monitored every other week in mice 
injected with overexpression cells. Metastatic disease progression was monitored twice a week in 
mice injected with knockdown cells. K12 and HOS overexpression mouse models were 
terminated at 24 weeks. HOS-MNNG knockdown models were terminated at 5 weeks. In all 
mice, the lungs were harvested and processed for histochemical analysis. 
 
Murine spontaneous metastasis assays 
Primary tumor growth was examined by orthotopic paraosseous injection of K12 and HOS 
overexpression cells (2 x 106 cells/ 0.1 ml of HBSS) or HOS-MNNG knockdown cells (2 x 106 
cells/ 0.1 ml of HBSS) into the left caudal gastrocnemius of 6- to 8-week-old female BALB/c or 
SCID beige mice, respectively, as described previously (Khanna et al., 2000). Serial primary 
tumor volumes were measured during the course of the experiment and tumor volume was 
calculated by the following formula: tumor volume (mm3) = π/6 x D x d2, where D represents the 
largest cross sectional diameter (mm) of the tumor and d the cross sectional diameter (mm) at 
right angles to D. Overexpression (K12 and HOS) and knockdown (HOS-MNNG) model mice 
bearing tumors approximately 15-16 mm in size underwent surgery to remove the left hind limb 
(amputation). The tumors were examined histologically. Overexpression model mice were 
sacrificed for examination of spontaneous lung metastases at 24 weeks post-surgery. For 
knockdown models, mice were sacrificed for examination of spontaneous lung metastases 11 
weeks post-surgery. In all mice the lungs were harvested and processed for histochemical 
evaluation.  
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Histopathology 
Primary orthotopic tumors and lungs of all mice were harvested and fixed with 10% formalin for 
24 hours and then transferred to 80% ethanol. Whole tissue samples were submitted to Histoserv 
(Germantown, MD) for processing. Histologic analyses were done using H&E staining. Serial 
lung sections were analyzed under light microscopy for the presence of metastases. 
 
Statistical analyses 
Differences among means were analyzed using independent t-tests. Survival curves were drawn 
and evaluated by Kaplan-Meier and log-rank methods using GraphPad Prism v4.0 (GraphPad 
Software, Inc., La Jolla, CA) and Microsoft Excel (Microsoft, Redmond, WA) software. 
Statistical significance was defined as a P-value of less than 0.05.  
 
RESULTS 
 
eIF4E is expressed in mouse and human osteosarcoma cell lines with differing metastatic 
potentials 
A panel of clonally related high- and low-metastatic mouse and human osteosarcoma cell 
lines were analyzed for their levels of eIF4E protein expression. We observed higher levels of 
eIF4E in highly metastatic murine (K7M2) and human (HOS-MNNG) osteosarcoma cell lines 
than in their clonally related low-metastatic  (K12 and HOS, respectively) partners (Fig. 5.1A), 
suggesting that eIF4E played a role in osteosarcoma metastasis. Next, using these cell lines, we 
sought to determine if eIF4E was necessary or sufficient for metastasis in osteosarcoma by 
examining the in vitro and in vivo consequences of eIF4E (upward and downward) modulation in 
low (K12 and HOS) and highly (HOS-MNNG) metastatic osteosarcoma cells. We infected the 
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low-metastatic (K12 and HOS) osteosarcoma cell lines with a lentiviral construct that 
constitutively overexpressed eIF4E (Fig. 5.1B).   eIF4E is a cap-binding protein responsible for 
the binding of the 7-methyl guanosine (m7G) cap structure found on the 5’ end of an mRNA and 
bringing it to the ribosome for protein synthesis. Using a cap-binding assay to assess the function 
of our overexpression constructs, we found that our forced overexpression of eIF4E in cells was 
functional (Fig. 5.1C). Conversely, stable suppression of the eIF4E gene was achieved by 
infecting HOS-MNNG with shRNA sequences that targeted eIF4E (Fig. 5.1D). 
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Figure 5.1. eIF4E protein is associated with metastatic potential in human and murine osteosarcoma cell lines. (A) 
Western analysis revealed higher total eIF4E in highly metastatic (HOS-MNNG and K7M2) compared to poorly 
metastatic (HOS and K12) cell lines. (B) Forced overexpression of eIF4E in poorly metastatic cell lines using a lentiviral 
plasmid that constitutively expressed c-Myc-tagged eIF4E. (C) eIF4E overexpression construct interacts with the cap 
complex. Epitope-tagged HOS cells overexpressing eIF4E (HOS-4E) and nonepitope-tagged empty vector control cells 
(HOS-EV) were incubated with 7-methyl-GTP cap beads or uncapped sepharose beads as a negative control.  
Immunoblots were performed with antibodies against c-Myc and actin. Input (I): proteins bound to the capped resin; 
Cap pull down (CPD): proteins bound to capped and uncapped resin; Negative control (NC) CPD: proteins bound to 
uncapped resin; Flow through (FT): unbound fraction after incubation with capped resin (C-FT) or unbound fraction 
after incubation with uncapped resin (NC-FT). (D) Highly metastatic HOS-MNNG osteosarcoma cells infected with 
shRNA lentiviral sequences that targeted eIF4E.  Stable suppression was achieved by infecting HOS-MNNG cells with 
an shRNA that targeted eIF4E. Sequences A and D had the greatest knockdown. Sequences D and A are shown as the 
knockdown and the negative control (NC) is a non-targeted shRNA. 
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Overexpression of eIF4E in osteosarcoma cells does not enhance cellular proliferation, 
migration, or anchorage-independent growth 
As eIF4E overexpression has been shown to play an important role in regulating genes 
that are essential for cellular growth and proliferation (Pestova and Hellen, 2000; von der Haar et 
al., 2004), we investigated its ability to enhance these features in osteosarcoma cell lines. 
Overexpression did not yield a significant change in cell number in mouse (K12, P = 0.46) or 
human (HOS, P = 0.47) cells (Fig. 5.2A-B).  Given the absence of influence of eIF4E 
overexpression on cell number and proliferation, we next asked if eIF4E influenced the in vitro 
metastatic phenotype of cells. To assess the role of eIF4E on spontaneous migratory capacity we 
used scratch (wound healing) assays in confluent cellular monolayers that were scratch 
“wounded” and allowed to “heal” for 24 hours. No increase in cell migration was seen following 
overexpression of eIF4E in either human or murine cell lines.  In fact, the overexpression of 
eIF4E in HOS cells resulted in a slightly slower migratory rate compared to the empty vector 
control (Fig. 5.3A). Using a second assay of migration, we evaluated the role of eIF4E on serum 
gradient-dependent transmigration. Cells in serum-free medium were seeded on culture inserts 
and the ability of the cells to migrate to the underside of the insert was determined in the 
presence of complete DMEM with 10% FBS. Like the scratch assay, the overexpression of 
eIF4E did not increase migration compared to empty vector controls in either human (P = 0.07) 
or murine (P = 0.15) cells  (Fig. 5.3B). Since the ability of cells to grow in an anchorage-
independent manner is associated with increased aggressiveness, we next asked if forced 
overexpression would affect colony growth on soft agar.  In anchorage-independent conditions 
(growth on soft agar), forced overexpression of eIF4E in HOS cells did not result in colony 
formation and there was no difference in K12 cells (P = 0.29) (Fig. 5.4).  Collectively these data 
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suggest that the overexpression of a functionally active form of eIF4E was not sufficient to 
convert the phenotype of low metastatic cell lines in vitro. 
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Figure 5.2. Overexpression of eIF4E in osteosarcoma cells does not influence cellular 
proliferation. A-B. Using a CCK8 proliferation assay, changes in cell growth were not observed 
following forced overexpression of eIF4E in human (HOS) and mouse (K12) osteosarcoma cell 
lines compared to empty vector (EV) controls over a 4 day time course. 
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Figure 5.3. Overexpression of eIF4E in human and murine cells does not influence cell 
motility/migration. (A) Scratch assay. Cells were seeded onto 6-well culture plates. Once confluence 
was reached, the cellular monolayer was scratch “wounded” with a P200 pipette tip and allowed to 
“heal” for 24-hours. Overexpression of eIF4E in HOS and K12 cells resulted in no difference in 
spontaneous motility over a 24-hour time course. (B) Serum-gradient-dependent Transwell migration 
at 18h. Cells were in serum-free media were seeded onto culture inserts in 24-well plates. The ability 
of cells to migrate to the underside of the insert was determined in the presence of complete DMEM. 
There is no difference in migration in human or mouse cells when compared to controls.  
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Figure 5.4. Overexpression of eIF4E in osteosarcoma cells does not influence anchorage-
dependent growth. Soft Agar assay. Cells were seeded at 2000 cells per 24-well tissue 
culture plate and cultured in 0.3% soft agar in complete DMEM for 21 days. 
Overexpression of eIF4E did not result in any difference in soft agar colony formation in 
HOS or K12 cells. No colony formation was seen in HOS cells with or without eIF4E 
overexpression. All images were captured on day 21. 
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Overexpression of eIF4E is associated with decreased latency and faster progression of 
primary tumor growth, but does not enhance metastasis 
Overexpression of eIF4E can promote tumor growth, as demonstrated by previous studies 
(Mamane et al., 2004; Wendel et al., 2004). The overexpression of eIF4E did not change the 
gross appearance of the HOS primary tumors. eIF4E overexpression resulted in a reduced time 
from tumor implantation to detection of tumor (tumor latency) and more rapid tumor growth 
(days from tumor implantation to amputation) than the empty vector control (Fig. 5.5A). 
Histological examination of the primary tumors revealed unencapsulated but well demarcated 
masses that invaded adjacent bone and skeletal muscle.  The densely cellular masses contained 
closely packed, spindloid to elongate mesenchymal cells arranged in bundles and streams 
supported by a delicate fibrovascular stroma. Anisocytosis and anisokaryosis were mild to 
moderate and mitotic figures were high. There was multifocal hemorrhage and necrosis. 
Following overexpression of eIF4E in HOS cells, tumors contained small clusters of closely 
packed, epithelioid cells arranged in cords (Fig. 5.5B).  Following resection of primary tumor-
bearing limbs, mice were followed for the development of spontaneous metastasis. No 
pulmonary metastases were seen in mice that received empty vector control or eIF4E 
overexpressing HOS cells.  No primary tumor development was seen following injection of 
control or eIF4E overexpressing murine K12 oseosarcoma cells into mice (26 weeks observation; 
Fig. 5.5C). To further examine the role of eIF4E on the in vivo metastatic phenotype, 
experimental metastasis assays were conducted with the murine and human osteosarcoma cells.  
Consistent with all previous data, mice given tail vein injections did not develop lung metastases 
24 weeks post-innoculation 
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Figure 5.5. Overexpression of eIF4E in HOS cells resulted in shorter latency and more rapid growth 
of primary tumors over time. Primary tumor assay, HOS and K12. (A and C) Volume measurements 
of control (EV) and eIF4E overexpressing (4E) tumors grown in HOS and K12 mouse models. 
Shown are the averages for the indicated weeks.  Overexpression of eIF4E in K12 cells is not 
sufficient to induce tumorigenesis in mice. (B) Morphologic comparison of HOS control and eIF4E 
overexpression primary tumors. Top and middle panels are from mice injected with HOS cells 
overexpressing eIF4E. HOS-4E tumors are composed primarily of spindle cells arranged in streams 
and bundles cells; however, these tumors also contain multiple clusters of epithelial-like cells that 
are often arranged in cords. The bottom panel is HOS control primary tumor. Here, the cells are 
composed of a monomorphic population of spindle cells. 
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eIF4E suppression affects tumor cell migration and anchorage-independent growth but not 
cell number  
Inhibition of eIF4E by small molecules, antisense oligonucleotides, and small interfering 
RNAs can reverse the malignant phenotype in some carcinomas (Kentsis et al., 2004; Moerke et 
al., 2007; Oridate et al., 2005). As such we asked whether suppression of eIF4E would influence 
the metastatic phenotype of osteosarcoma cells in vitro and in vivo. Suppression of eIF4E in the 
highly metastatic human osteosarcoma cell line, HOS-MNNG had no effect on cell number (Fig. 
5.6). Cell migration was first assessed using a scratch assay for 12 hours. Cells with knockdown 
of eIF4E had a significant delay in migration compared to controls (P < 0.001) (Fig. 5.7A). Next 
we evaluated the role of eIF4E using a serum gradient-dependent transmigration assay.  Again, 
the knockdown of eIF4E resulted in significantly decreased cellular migration compared to 
control (P < 0.001) (Fig. 5.7B). Finally, in anchorage-independent conditions, the suppression of 
eIF4E in HOS-MNNG cells did not prevent soft agar colony formation; however, the knockdown 
did significantly (P < 0.001) reduce the number and size (Fig. 5.8) of colonies compared to 
controls.  
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Figure 5.6. Suppression of eIF4E does not affect cell number. CCK8 Proliferation Assay. 
Cell growth curves demonstrated knockdown of eIF4E produced no difference in cell 
number in human (HOS-MNNG-A/D) cell lines compared to negative controls (HOS-
MNNG-NC) over a 4 day time course.  
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Figure 5.7. eIF4E is necessary for rapid cell motility/migration. (A) Scratch assay. Cells were 
seeded onto 6-well culture plates. Once confluence was reached, the cellular monolayer was 
scratch “wounded” with a P200 pipette tip and allowed to “heal” for 12-hours. Suppression of 
eIF4E in HOS-MNNG cells caused decreased motility when compared to negative control cells 
(NC) over a 12-hour time course. (B) Serum-gradient dependent Transwell migration at 18h. 
Cells in serum-free media were seeded onto culture inserts in 24-well plates. The ability of cells 
to migrate to the underside of the insert was determined in the presence of complete DMEM. 
There is decreased migration in HOS-MNNG knockdown cells when compared to controls. 
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Figure 5.8. eIF4E suppression decreases anchorage-independent growth. Soft Agar 
assay. Cells were seeded at 250 cells per 24-well tissue culture plate and cultured in 
0.3% soft agar in complete DMEM for 21 days. Suppression of eIF4E in HOS-MNNG 
cells reduced the number and size of colonies that formed in soft agar. All Images were 
captured on day 21. 
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Suppression of eIF4E in a mouse xenograft model reduces the number of spontaneous but 
not experimental pulmonary metastases 
The biological behavior of the primary tumors in which eIF4E was suppressed was 
virtually identical to the controls. Both tumors had the same percent tumor take, latency of 
primary tumor growth, and a similar rate of progression (Fig. 5.9A). The gross appearance of the 
HOS-MNNG knockdown tumors and the negative control tumors were also similar. Histological 
examination of the both the knockdown and control tumors revealed unencapsulated, but well-
demarcated masses that invaded adjacent bone and skeletal muscle.  The densely cellular masses 
contained closely packed, spindloid to elongate mesenchymal cells arranged in bundles and 
streams supported by a delicate fibrous stroma (Fig. 5.9B). Anisocytosis and anisokaryosis were 
moderate and mitotic figures and apoptotic bodies were numerous. There was multifocal 
hemorrhage and necrosis. Following resection of tumor-bearing limbs, mice were followed for 
spontaneous metastasis to the lungs.  Mice were sacrificed based on signs of metastasis-related 
morbidity. Necropsy examination confirmed lung metastasis in all mice. Following death of 
approximately 85% of control mice, remaining mice were sacrificed to evaluate the relative 
tumor burden. Grossly, pulmonary metastatic nodules were observed on the surface of both 
knockdown and negative control models. Grossly, knockdown mice had fewer and smaller 
metastatic nodules than the control mice (Fig. 5.10B). eIF4E suppression resulted in well-
defined, 1-3 mm round, slightly raised, white to tan pulmonary nodules that sometimes coalesced 
to form larger nodules of variable size and shape. Control lungs had similar lesions but the 
metastatic nodules were sometimes slightly larger (1-5 mm) and formed larger coalescing masses 
more frequently. Histologically, pulmonary masses consisted of mesenchymal cells that look 
similar to the cells observed in the primary tumors for both knockdown mice and controls. 
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Furthermore, the suppression of eIF4E inhibited the pulmonary metastatic potential of the HOS-
MNNG cells compared to the control model (Fig. 5.10A). To further examine the metastatic 
phenotype we used an experimental metastasis assay. The aggressive nature of this model 
resulted in the rapid development of metastasis in all mice (Fig. 5.11).  Post mortem examination 
revealed that the size and distribution of the metastatic nodules was not influenced by eIF4E 
knockdown. 
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Figure 5.9. eIF4E knockdown in HOS-MNNG cells does not delay tumor formation. Primary tumor 
assay, HOS-MNNG. (A) Volume measurements of control (NC) and eIF4E knockdown (A/D) 
tumors grown in SCID mice. Shown are averages for indicated weeks. Suppression of eIF4E does not 
influence tumor formation and growth in SCID mouse xenografts. (B) Histologic and 
immunohistochemical comparison of control and eIF4E knockdown primary tumors. Histologically, 
both control and knockdown primary tumors were composed of monomorphic spindle cells arranged 
in streams and bundles. Only control primary tumors express eIF4E. 
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Figure 5.10. eIF4E is required for spontaneous metastasis, but not experimental 
metastasis. Following orthotopic paraosseous injection of control and eIF4E knockdown 
HOS-MNNG cells into SCID mice spontaneous pulmonary metastases developed. (A) 
Knockdown of eIF4E in HOS-MNNG cells results in a less aggressive model phenotype 
with a longer spontaneous pulmonary metastasis associated morbidity free interval 
compared to control HOS-MNNG cells. (B) Suppression of eIF4E in HOS-MNNG cells 
results in fewer spontaneous metastatic nodules compared to controls. (C) Injection of the 
same cells into the tail vein (experimental) gave rise to lung metastases without 
differences between the control and knockdown. 
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DISCUSSION 
eIF4E overexpression has been associated with malignant transformation and cancer 
progression in a number of settings (De Benedetti and Graff, 2004). Overexpression of eIF4E is 
hypothesized to selectively enhance translation of metastasis-related genes (e.g. cyclin D1, 
VEGF, survivin, and MMP9), which are necessary for cancer cells to progress through the 
metastatic cascade for the successful establishment of metastases (De Benedetti and Graff, 2004; 
Zhou et al., 2010).  In this study, we explored the role of eIF4E in osteosarcoma metastasis, 
taking into account its known role in malignant progression in some carcinomas. We observed 
that clonally related mouse and human osteosarcoma cells differentially express eIF4E. Western 
analysis revealed higher levels of eIF4E in highly metastatic mouse (K7M2) and human (HOS-
MNNG) osteosarcoma cell lines than in their clonally related low metastatic (K12 and HOS, 
respectively) partners. This finding provided the basis to select cells based on eIF4E protein 
expression levels to study the in vitro and in vivo consequences of its modulation. Thus, K12 and 
HOS cells were selected for overexpression studies and HOS-MNNG cells were selected for 
knockdown studies to further investigate the effects of enhanced and suppressed expression of 
eIF4E on metastatic behaviors such as tumor cell proliferation, motility, migration, anchorage-
independent growth, tumor growth, and metastasis.  
Cellular proliferation is important in cell cycle regulation, tumor progression, and 
therapeutic response. Overexpression of the eIF4E oncoprotein plays a critical role in cellular 
proliferation by enhancing the translation of a subset of mRNAs (cMYC, CDK2, cyclin D1) 
involved in important cellular processes that are implicated in oncogenesis associated with cell 
proliferation (Konicek et al., 2008; Silvera et al., 2010).  In contrast to what is observed in many 
carcinomas, we found that modulation of eIF4E expression did not affect proliferation of 
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osteosarcoma cells. Suppression did not inhibit HOS-MNNG cell growth nor did forced 
overexpression enhance cell number in K12 and HOS cell lines.  
There is a large body of experimental and clinical data documenting that carcinoma of the 
breast, lung, colon, prostate, and head and neck contain elevated levels of eIF4E.  In addition, in 
animal models, eIF4E overexpression is correlated with increased number of tumors, invasion, 
angiogenesis, and metastasis (Crew JP, 2000; De Benedetti and Harris, 1999; Zimmer et al., 
2000).  In this study we show that forced overexpression of eIF4E in mouse (K12) and human 
(HOS) osteosarcoma cells is not sufficient to change the metastatic phenotype of poorly 
metastatic cells to a more aggressive phenotype in vitro or in vivo. Despite the fact that 
overexpression of eIF4E did not change the metastatic phenotype of HOS and K12 cells, we 
observed that while forced overexpression of eIF4E did not enhance cell number in vitro, it was 
however associated with a shorter latency and more rapid progression of primary tumor growth 
in HOS cells.  A possible explanation is that eIF4E overexpression provides a late growth 
advantage for HOS cells. In which case, its influence is more likely to be observed in long-term 
assays such as the primary tumor growth rather than short-term in vitro assays.  
Tumor-cell migration is a prerequisite for invasion and metastasis. Zhou et al, showed 
inhibition of eIF4E by small interfering RNAs (siRNA) effectively inhibited motility and 
suppressed colony formation in triple-negative breast cancer cells (Zhou et al., 2010). We 
observed that suppressing eIF4E influenced spontaneous and serum gradient-dependent 
migration of human osteosarcoma cells similarly.  eIF4E inhibition reduced the 
motility/migration of highly metastatic cells. Additionally, we demonstrated in anchorage-
independent conditions, suppression of eIF4E in HOS-MNNG cells resulted in colonies that 
were reduced in both number and size. In the in vivo knockdown model, spontaneous lung 
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metastases were reduced in number and size compared to the control. There was no discernible 
difference in experimental metastases between the knockdown and control. Tumor take, primary 
tumor development, and growth rate were similar in the knockdown and control mice.  Again, 
the fact that a difference was observed in the spontaneous metastasis (long-term) assay but not 
the experimental or primary tumor (short-term) assays suggests that eIF4E expression provides a 
late advantage in growth.  
In summary, forced overexpression of eIF4E alone did not change the metastatic 
phenotype of poorly metastatic human and murine osteosarcoma cell lines in vitro or in vivo. 
However, suppression of eIF4E resulted in reduced migration, anchorage-independent growth, 
and spontaneous lung metastases. Taken together, our results suggest that eIF4E likely plays a 
necessary role in the molecular strategy adopted by osteosarcoma cells to achieve metastasis, but 
alone is not sufficient for motility/migration, anchorage-independent growth, tumor formation, 
and metastasis.  Still, targeting this gene may offer clinical benefits in these tumors.  Our 
observations on eIF4E constitute, to the best of our knowledge, the first report on the biological 
role of eIF4E in metastatic osteosarcoma. Overall, this study provides evidence that both eIF4E-
dependent and eIF4E-independent mechanisms contribute to tumorigenicity in osteosarcoma 
cells. Because our study is based mainly on a single, clonally related human osteosarcoma cell 
line, exploration of eIF4E expression in additional human osteosarcoma cell lines will be 
required to accurately define the role of eIF4E that we report in osteosarcoma metastasis. 
Currently, there is very limited information about eIF4E expression and activity in cancers of 
mesenchymal origin, including osteosarcoma. Assuming that eIF4E plays a similar role in 
osteosarcoma as it does in multiple carcinoma types, we propose that therapeutic strategies 
targeting eIF4E may improve the outcome for osteosarcoma patients. Current strategies designed 
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to target eIF4E in cancer malignancies such as breast, prostate, stomach, colon, lung, skin, and 
the hematopoietic system (Hsieh and Ruggero, 2010) include antisense oligonucleotides to 
eIF4E, RNAi or antisense RNAs that suppress eIF4E, a physical mimic of the natural ligand, 
suicide gene therapy, and peptide-based inhibition of eIF4E (Ko, 2009). Our results suggest 
targeting eIF4E in osteosarcoma may offer clinical benefits.  
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Chapter 6. Conclusions and Future Directions 
 
 
 
 
The development of metastases, most commonly to the lung, is the cause of death for 
most osteosarcoma patients. Long-term outcomes for osteosarcoma patients have not improved 
in over 20 years (Meyers, 2009). The primary research need in the field is to understand the 
biology of metastasis in osteosarcoma so as to improve outcomes for future patients. Unraveling 
the complexity of metastasis demands a focus on new tools, reagents, and biology in order to 
investigate hypotheses.  Accordingly, this body of work introduces an outcome-linked human 
ostoesarcoma tissue microarray (new tool) and an ex vivo pulmonary metastasis assay (new 
reagent) that allows real-time assessment of metastatic progression.  In addition, we describe for 
the first time, the biological role of eIF4E (new biology) in metastatic osteosarcoma. The goals 
of this research are to utilize these new tools and reagents to identify proteins and/or processes 
that define the metastatic phenotype of osteosarcoma and to use our newfound understanding of 
eIF4E in osteosarcoma metastasis to develop novel therapeutic strategies to prevent growth of 
metastases and improve treatment outcomes for patients. 
 
Human osteosarcoma tissue microarray (TMA) 
In this work, we have described a human osteosarcoma tissue microarray (TMA) that we 
believe will aid in the advancement of our understanding of both metastasis biology and 
therapeutic strategies. We used this tool to detect and validate protein biomarkers across a 
variety of patients. Our outcome-linked TMA was constructed to compliment other TMAs 
currently available and address the limitation of small sample size while providing a wider 
variety of sample types that characterize the disease including pre-treatment excisional biopsies, 
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post-treatment definitive resections, and lung metastases. Eighty-nine tissue specimens collected 
between 1984 and 2001 were obtained from 75 patients (35 males and 40 females) undergoing 
resection of osteosarcoma of the extremities, pelvis, and craniofacial bones. A variety of 
anatomic sites and histologic subtypes (see Table 3.1) were included.  Using these tissues and 
associated clinical annotation, a schema of tissue cores, arranged according to the sample type 
(biopsy, definitive resection, or resection of distant metastasis), was developed. Final patient 
specimens included: 21 primary biopsies (19 patients), 48 definitive resections (47 patients), 20 
metastases (14 patients), and 12 control tissues (see Fig. 3.1). As an example of our TMA’s 
utility we evaluated the immunohistochemical expression of eIF4E in osteosarcoma tissues 
formatted on this array and assessed correlations between eIF4E expression, sample type, and 
overall survival. Our findings demonstrated relatively uniform expression of eIF4E in both 
primary tumors and metastatic lesions of these osteosarcoma patients (see Fig. 3.2A) and that 
eIF4E expression intensity was not an independent predictor of overall survival (see Fig. 3.3B).  
 
Pulmonary metastasis assay (PuMA) 
Here we described an ex vivo pulmonary metastasis assay (PuMA).  We used this assay 
to evaluate novel therapeutics that specifically target metastatic progression and metastatic 
lesions in a timely manner. This closed system and sterile assay allowed real-time assessment of 
the metastatic progression of GFP-labeled cancer cells, from a single cell to the formation of 
multicellular clusters, in the mouse lung microenvironment for up to 21 days. To validate the 
utility of the PuMA for the study of metastatic progression, we compared previously described 
highly metastatic versus poorly metastatic clonally related human (Rhim et al., 1977) and murine 
(Khanna et al., 2000) osteosarcoma cell lines.  This model faithfully predicted high- and low-
 142 
metastatic phenotypes of human and mouse cancer cell lines (see Fig. 4.4A-D). The clonally 
related variants with greater metastatic propensity in vivo were also associated with greater 
metastatic phenotype in the PuMA.  The PuMA fills and unmet need in the study of metastasis 
biology and therapy by allowing the real-time assessment of metastatic progression in a relevant 
tumor microenvironment. Furthermore, it is a useful tool for translational drug development as it 
allows for assessment of multiple drug doses, exposure times, and schedules. 
 
eIF4E and Osteosarcoma Metastasis 
eIF4E overexpression has been associated with malignant transformation and cancer 
progression in a number of settings (De Benedetti and Graff, 2004). Overexpression of eIF4E is 
hypothesized to selectively enhance translation of metastasis-related genes (e.g. cyclin D1, 
VEGF, survivin, and MMP9), which are necessary for cancer cells to progress through the 
metastatic cascade for the successful establishment of metastases (De Benedetti and Graff, 2004; 
Zhou et al., 2010). In the current study we sought to define the biological role of eIF4E in the 
metastatic phenotype of osteosarcoma, by stably overexpressing and knocking down eIF4E in 
poorly and highly metastatic mouse and human osteosarcoma cell lines respectively, and 
evaluating various steps of the metastatic cascade in vitro and in vivo. We found that suppression 
of eIF4E decreased cellular migration, anchorage-independent growth, and metastasis in vivo of 
human osteosarcoma cells (HOS-MNNG) whereas, forced constitutive overexpression of eIF4E 
in both mouse (K12) and human (HOS) osteosarcoma cells did not enhance cellular migration, 
anchorage-independent growth, proliferation, or metastasis. Collectively, our data suggest that 
eIF4E is potentially necessary for metastasis in osteosarcoma as inhibition of eIF4E was 
effective in suppressing the metastatic phenotype in highly metastatic human osteosarcoma cells 
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(HOS-MNNG). Conversely, and not surprisingly, forced overexpression alone was not sufficient 
for poorly metastatic mouse and human osteosarcoma cell lines to achieve a metastatic 
phenotype in vitro or in vivo.  
 
Future Directions 
While the expression of eIF4E in osteosarcoma cells and tissues along with evidence 
linking its inhibition with a suppressed metastatic phenotype are encouraging, our study is based 
mainly on a single, clonally related human and mouse osteosarcoma cell line. Therefore, it is 
necessary to explore eIF4E expression in additional human osteosarcoma cell lines in order to 
more accurately define the role of eIF4E in osteosarcoma metastasis. Presently, there is very 
limited information about eIF4E expression and activity in cancers of mesenchymal origin, 
including osteosarcoma. It is possible that through our work we may have identified a valuable 
new potential target for treatment of osteosarcoma. Assuming that eIF4E plays a similar role in 
osteosarcoma as it does in multiple carcinoma types, we believe that therapeutic strategies 
targeting eIF4E may improve the outcome for osteosarcoma patients. Current strategies designed 
to target eIF4E in various carcinomas and the hematopoietic system include antisense 
oligonucleotides to eIF4E, RNAi or antisense RNAs that suppress eIF4E, a physical mimic of the 
natural ligand, suicide gene therapy, and peptide-based inhibition of eIF4E (Hsieh and Ruggero, 
2010; Ko, 2009). Given that progression through the various steps of the metastatic cascade are 
likely to be similar in many cancers, an important next step would be to assess agents that may 
already be in development or in clinical use for carcinomas in preclinical and clinical studies in 
osteosarcoma. The PuMA could be used to assist in the assessment of novel therapeutics, 
evaluating multiple drug doses, exposure times, and schedules. Our data support the concept of 
 144 
evaluating these new agents in preclinical models of sarcoma as well as in dogs with naturally 
occurring osteosarcoma. 
To date, significant information has been accumulated regarding targeting eIF4E in 
carcinomas however the potential of targeting eIF4E in osteosarcoma has yet to be realized.  As 
such, control of protein synthesis has emerged as a new research area with significant potential 
for developing novel therapeutic approaches in the treatment of osteosarcoma. Protein synthesis 
is tightly regulated at the level of translation initiation. Our over-riding hypothesis suggests that 
eIF4E expression will define the extent to which specific “weakly” translated (or metastasis-
associated) mRNA transcripts are translated. Cells with an enabled translational machinery will 
be able to respond to the dynamic events associated with moving through the metastatic cascade 
by expressing these needed proteins on time at the appropriate locations within a cell. We 
hypothesize that this enabled ability to express proteins in a dynamic environment will contribute 
to the metastatic propensity of a cell.  Identifying potential metastasis-related mRNAs that are 
differentially regulated following eIF4E overexpression or suppression in osteosarcoma would 
be an important and potentially clinically relevant question in this area of research. Western blot 
analysis of previously described “weakly” translated proteins likely to be linked to metastatic 
function (see Table 2.1) would generate a list of proteins differentially expressed in 
osteosarcoma cells. From here, quantitative PCR could be used to examine the proteins at the 
transcriptional level to confirm that any differences are, in fact, the result of translational 
regulation of their expression. In addition, a non-candidate approach, polysome expression 
microarray techniques, based on identification of mRNA transcripts that are expressed with 
multi-unit ribosomes (so called heavy polysomes) would allow the identification of unique 
putative “weakly” mRNAs that are differentially expressed following eIF4E modulation that are 
 145 
destined for translation by virtue of their association with multi-unit ribosomes. Finally, this 
improved understanding and discovery of new targets involved in translation will facilitate the 
use of novel inhibitors of eIF4E and translation initiation currently under development in our 
laboratory and elsewhere to be used in the treatment of osteosarcoma. 
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